var title_f14_43_15024="Thyroid anatomy PI";
var content_f14_43_15024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F66834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F66834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Thyroid and parathyroid glands",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 500px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thyroid is a butterfly-shaped gland in the middle of the neck. It sits just below the larynx (voice box). The thyroid makes two hormones, called triiodothyronine (T3) and thyroxine (T4), which control how the body uses and stores energy. The parathyroid glands are four small glands behind the thyroid. They make a hormone called parathyroid hormone, which helps control the amount of calcium in the blood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15024=[""].join("\n");
var outline_f14_43_15024=null;
var title_f14_43_15025="Bupranolol: International drug information";
var content_f14_43_15025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bupranolol: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4323559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adomed (AT);",
"     </li>",
"     <li>",
"      Betadran (FR);",
"     </li>",
"     <li>",
"      betadrenol (DE, IT);",
"     </li>",
"     <li>",
"      Monobeltin (ES);",
"     </li>",
"     <li>",
"      Ophtorenin (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1978078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Bupranolol Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta-Adrenergic Blocker, Nonselective",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta-Adrenergic Blocker, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Ophthalmic: Management of glaucoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Oral: Management of cardiovascular disorders",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Oral: 100-400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Ophthalmic: 0.05% to 0.5%",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Capsule, extended release: 160 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Solution, ophthalmic: 0.25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 10 mg, 40 mg, 80 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10348 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-197.136.42.3-858ECED34C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15025=[""].join("\n");
var outline_f14_43_15025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4323559\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978078\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978080\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978083\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978079\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821062\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978082\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10348\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10348|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_43_15026="Disseminated granuloma annulare - annular lesions on leg";
var content_f14_43_15026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disseminated granuloma annulare",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 55 year-old patient presented with disseminated granuloma annulare in a brightly erythematous annular and arcuate pattern demonstrating complete central clearing. Scores of similar lesions were present on the trunk and extremities sparing the face, palms, and soles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15026=[""].join("\n");
var outline_f14_43_15026=null;
var title_f14_43_15027="MRI Focal cortical dysplasia";
var content_f14_43_15027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F65171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F65171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI showing focal cortical dysplasia in the left temporal lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 397px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGNAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Wyc8dTSe9OII6jH1pDxQAmaM8UoHHT6UmD3oAM0fjTxjbgj5qWKJ5WAUZJNAEYznjOasx255aY7VHJHepl8qzAJTfNnucYqCRZJ5N7KRu79qAHtciMCOBRx0bvVcs8jEsxJqUDy0ycEkYGBUJOWG49KAHFgsh6MO2aHmdh+nHFM6nPXNKyEYyOtADcn1pcEjODjpUywhWAZWb2A5pkmN2BnA7YoAZ06UA/nUu3AKjufxFNJVQVHPqcUAIQwznIxTeQODV62sLq9mWOytZ7hmPyhELZrtPDnwf8Z6848nSmtY+pkuWEYA9TmgDz0dMnn8aFBPQH2xX0bo/wCzLdFwNZ8R28KMPvWsPmjP1yK7n/hTkei6WqaWdDuJISATc53yfQDOCfSgD44pQGxkA4Fel+PtCh0PWri01S3jtLt8yeSqhBHk9vUe4ribphGyrBPvT0VB/nFAGTk05SuQTu6dvWup0/wzreseXBpmhy3Msx2o0UZJb39q7i6+CWtWdnHcaxcJYttAMDDLgnthc0AeO9ByaBycHNe32/wh0K7gVm8Spb3AUb42Q4U+5Pv2rznxD4bGj6o1lbzSX7MdsckKna57AdzQByp60c19AeFP2dtXvNNd9dc6ffyR+bBEVVwRjPzHPB9q818f+Br3whqKWs+JlYZ3qpHbofSgDie1GT61OsasBtUkd+eh+tRhGDHOBg4yTQAiOVOQSD6inkq4JJw3160FWbPQ+/AzTVbaeQDx3oAlgnaFhtyVPb0qeQwTvwQD1HOD9Kpq20cZB9RRgH2P8/pQASIUI5yDUdTbRkBtwA9sVLJbIBujdmUck7elAFSinbeCQelKFBU880AMopcUEDOM8etACgn1ooxRQA+ZlbkE5HGPamoQOvWkPfrQAe3NAD2P3euAPyoTYSdx/Sm8DkYOf0oALMAAc0AOUjd8ox2HGTWnZy21jFIZE3XTDaueQvvVeJUtVLN88pwNo7VXkYn5yvXjJ9frQBfkurIshEbuxO6Rn747VvL4i0T+y2gGmOs5PDZB4rjs98fjTSCRnn3oAnu5RNcMwQqCeAKZtAQlhyegNNjwCNx4z1p5bDFgATmgBVfoAFAH60+QeXNkPk4ye1Ru2Fwp/EVYsbXzg00ok8iPl2Az+FAD7W3uJHieFJACeHVSdx/rXpHhn4OeIddsxezsNPsznbNPwX98dcVqfBbRYtW1SO72Mljbjl5sAcHoPf6V9H3+vaXZWbBpEFnCm4xggt8vRePWgDyvQ/gH4Zs7NrjVtTuLttoy52rHHkcsfUVoaRF8MPC0yxWsmn3c6H5pTa+YWb6GuT+IPxFudetPsfkC0tFbMEUY27u2X9a8xkuUt51kRn80jHI5J9aAPpzT/iB4US4eOXUY7WB2yRbWqxnHbGPfrWL4h+K+hQ33ladbSXCDI8+cklgPSvALeZWVdrASAZJ2nnPXFLeXCqVD/fGAq9vz7UAfR3hvxnpGsGRJYfOLjAUuTsJ9q7S9tfCyxQs15DpUhAcKkoJ/EV8paBqX9mz/AGxiV+XKj+8fr6VBqOqzahNcTXEzPM7YJP8ACAPTsM0Ae1fGHw5D45023tJJLdb60Vm02/hUEXXH+qc9RyOK+b/B3hjVdd8Sx6TbwyJKJdk5IwYwD830xg16T4E1eaxufLe4LRzgY3EkK/UMvvwa9G+DWl21v4m8aavdyKJ7eZAkqjAKszs2706UAep+CfDdp4b0lbHT1DqvLSdWJ/vE9T9BW7awm3mlluBHJGylsOo+bHpn1rwrxT8Y5Y7mWPR7dY1Ugbh3weo/Co9L+MtzJLYi8UsfmySOCewPpx3oA9vv9H0y/Qrd2dozshxGqBSvHXjv3rk/CemaRbPttdOt/tcYy7Sp8ytuOCD/AIVreGfEtjr8O9B5MpG4px8+OmK5X4ueIv8AhGNKiSxZYb+7diJhngL1B9Dk4BoA7u5by2KSXEDO+CyhwGU+ozXF/E3wCvi/SEdCqzR5ZVVh84A5ye9fNWp6vfXF39pvbibeT98SE/5NdV4N+IWoaTIFmkee3jwvlOxGSe+49DQBwnxE+H2qeGF/tEQP/Zsj7WYA4if0Psexrgd2M55+tfbfh/x74e8SadNZ6vEgW4Xypop0BDL9P61498VfgfJp8T654HLX2nNmRrTrJF/uf3h7daAPBsgqABkg9aIeG4UE9valljeGR45UaN1OGVhgg+hFGdxyx57kUAG18ZAJxnOB0oR9vcj6U7p/HhOgweDTSAzHHy+xoAc77uQMZ+UEmlEhVxn5gP4ajyVJwQeMdOMU5HAXIyWH+eaAJnjjK7oxwByP8aqng5HNSRysjlhjnqCODUtxED+8iwAedvpQBWU4zxzSdTSkkHqaPWgBQD6UUgNFAB3pdxX7ppVKrkkZbt6U3d196AADJA7mrabbXDyZMhzgelTWQighke5Ub9v7vI70zfC23fA8jsN2d2Pw+lAEG9pCSfv5+U4qFwQSCfrWu+owC0eI2arcEYDhs4rJLBmJA/OgBlPUcHPJ9KdHgDbtBY9CacrhYzgEsepoAZnDgsOc0DbuDH8RRkfeYA5Fafh7QtQ1++W30+AyuTgt2UepNAEGiaVd63qcVnYxl5pDjgcAete9T+GtB8M+FYtO1idnu2G5ool+c98t6V3Xw0+Gdt4c02BxOn2vIkmJQN5ijqB6cV4r4qv57/X9TuZ2+aWdjz1x0Cj6CgCTU9aM9haWFov2LTLVy0USdST3J6k1Z0TVPMtLy1LtMCMh2fgAdvfFcdqEkkoYgsHwFUjBx7Vb0fVI4I8lR8q7GUnPGMEigCG8uCbtpJDmbPX2HTHpVKS48xizk7uckev41Jct507btpTd24I/+tVU4R97H93u5APLfSgC7ZlvNjD8jdtY5+8SOPwqeBUlMjBARECpHO0NnGM1jxTFJt5f5AwIwen410GjyIljI8vy2+4yH364FADLtkj2w4aRwgJC8YOO309KzpY2klIDKy+YAxXgdM9aLi6eISMm7zpwcbuqrnp9cVJbQvPIXXO1HAAA4BxyaAN7RnLXaSKw3AEsuOAACPzr0+O8udJ8C+PEUkzXV3b2pJPPO8np24rifDemSXRgCoRHJMkQYDBkJIzmu41DT3vND+JUbSbzZa1Gw2AjgGQY/wDr0AeN3TPHbkBQ5z8pU9OfWobeYidckH5Dx+n6VNe7iy4zGM5CjkjnnFY87EvGcFRtywHck9qAPVPhv4mn0jxBaCVwbUuI5Bu+6Ccce1dh+0aQdc0aNXEqi2ZwSCAdzZxXh+mzb7dXQDI539MV6D8T9eXVotDnDfaDFp6JLjj5/wC79RQB5zeTEvNE7qSwyAB0I9Kjgl2Qja3mgk5HX06ms6LzLq9YwsVRn5cjPHpXZ+HfDr3FrJOm2O3BKs8g+/8A/X+lABoszSXcYbt2HJUn0x/Kvo3wJqc+laDbowluJy+YIUUkj3PpXiGk2NvBfxrbMS+4AyemPavXvCmsR6HoE0simbecOjffxk/OD/SgDO+MHwqt/G011qmkiGz1VF5YjC3GB0I6A+9fJup6bdaTfzWl/C8M8LbXVhyP8a9z8R/ELV5tUkfT7+SCAMWUIOGGehrN1y8s/iNHFFqxS21yPCRXyrtVxjAR1HHXvQB4sr7cFQCR/npSAls4HJ/PitHxDpF94f1KbTdRiMc8Z5BHX6Vm9QSvAx0zQAm0lsHGaTkc1IuTnjPpmkfbg7QfqaAE3BhggD0qa3bD7XIwcd6rk88807koB2zQBNe20lvM27BXruByKrGrcM3mDypzuUjg+lRXEZhYrnKnofUUARDpRSrjHT9aKAGmrtvbqq+ZPwOyg80WUI3q8mBGDnJPGRTZ5d0shVlCk56dqAI5pmkbcxOOoBqYhkgVpcFsfLk8gVDEo3Egbh1APQUkpyDuJ3ccdaAI2O4Z7+tPjCnAYn3pgCnrx70pOfuk7qAHSSDIC42jkcUz+AnPJPTFPt4pLiVY4o3kkcgBVGSTXrXgP4Oapql5E2sW0lujjfHbyZUsPVj6fTmgDzzw74eudauF2bUts4aQnA+gHUmvevCX9leCNMW0m0yeO7kG5jPghzngkevsava4vhjwTLDDDFDqWswLiLy49kNuOOCP4mB9a8u13Wri6vp7i4mE0rtuJJzg9aAPpfwX4ng1SUW0tvGzyphAvBH09K+c/FkTw67frKoLCVwCCSBye1dB8NtelTXoAkjAl1+8ec9xn3rO+JZRvF2rNGSqeaTkHnB9PpQBxMo2szeWpCjJI6/XHesiVfLkymCHPBU4xW1JE3mMe687R2471m6kkUEQdCVYkBiB0OOCtAAJpMk5Mh6kd/b8KikfIZ2YAN3A5+gFQ2czEOhIUYHP8X41O7gpkj94BkNj73rxQBTl5bbyckDAzk4rTub0RWKwoVIbBKgdlH+NY5kKSgKS23qehpP3k84AJDMwABoAuQM0z+acsSdxOeR+FdboMNv5skjTfKx49eR0xXHK2yZkhPJGGYnGa1tLuFlnLdF3Ak4x+XtQB7d4UvtI/trQLISGJVuFklfHHtu7V13wstl1af4uRSFW87VXjAAHzcyEVxXwPs4b/wARObhVdCqhw65UJn9D0rvv2e7VZdR+IqEH/kPMA2MEff4FAHj3iDw09vdTbVkUoPlXBI9zmuXvdDdIIX5Z0TqR78fSvpnxf4deHUbwxxbo0jBGeQQScg15n4i0om3DGMbjCAcZX8qAPCDLJp9yyxDchzuUencVNfay88flp8sI4Hrg1Lr9o8BeUHJUkA+2e9YJkKNtUHOMZ445oA6fwZpsl3fKowUY5K9AAOSc/Su61u9t0RYbF91lCvGzr/nPeuR8O3RtrG5eBgkjoIwM9ieSPyqrb3hjZzG7NIzbQDyCPcUAdPpeqOlyZiMFDgL2z/dFd+kk3/CHXd2GZSYtx9QeeP1ry7TsTTocFWAzgZ5PYiu517UFh8B2NvE6rcXLvvJJztHt0GMUAeVXk/kyJ8p5BypPU+v51a04yBfNjwQTg46jHb61j6lIZ9T24C7R0J4PvXc+APDkmpaksUchjhX55yy5GzHP4mgD1jUPAVt8QPhxo17fhYNaNphJwByqkhd1fM3irw1qXhfVXsdZt3glHKnHDj1Fe/eL/iRcQP8AYPDqiytrVRHswGIAA4B71zF54pg8TWgsfGNql6qnYk4ULPET0Kt3HfFAHiGcHPH4UhbnAPFdZ418E33hkxXSkXek3BzbXiD5XHoR2PtXKHggEbWBwc9KAE9QRx2xTotudr4+o7GkL5UKBwKauM80APkJz8w57HFWIWiljMbk7j0J65pgVZFzv+YdOuKjcg4KriTPOOlACvG0bFSCfxorWtR5sCskYfsTt6GigCndBJMIpAEfGexqskau2FPC9TipGAEZAU7zgZ7U1MJEdmQ3c+1AD5ZFjUrGAGPpVTvn0oJJPJ56VJjgNt68fX1oAYeTk4A+laXhzQr7xBqKWWmQ+bO2TjOAAOpP0qhDE1xPHBArNK7BFUclmJwMV79p/h+3+H/hySykZX125QPeTJz5QPSIH26mgCDwdp/hjwLB9o1GM6pq3PIA2qR/dB7Z79av+J/iff30LNp3+iJsCF1OXK/3Qe3Nefa1JmVQ2W77yeB+FYl1cB5BJubAOFUccepoAv6lqrzSeYzMzk7nDMSd3pWLLP5xLsuMfw54H0qGaQglmfIPTPApHmJXjk/cx2oA63wZcmG+h8kqmGGGzyp7HNaviASNJJcybi8jfNx82T2/+vXH6PPskBVsYO4tXfWJh15U3hROE5VsHIHcH3oA4O7lYlxsVRITls5I/wAapXiPIpVSCAwIz+ldtqvh2RJ5MBlBGSRj/PFYs+neWpKriQ9F7CgDnUUW6j5Cd5zjrn6+1LPMUTaoGW4NW7yB080FjvZhggDGe/6VnSuoC5GApzz3xQBWMe3OWG4DPXpUgYiLBzvPAPSo5ZCwLMdjZ9OtLgYGcM+dpB4oAmtk3YZkDH+FccY5rpNLszEG8zIcvlcfyqpoVjLOyugYzk4XA9uld1ax2WkKXvozdXgAYQKfkQ/7Z7/QUAezfBzwvpen6TZLrkLG81py1opBAMaENk47nrWt8ALRo7vx75shXGvzMrY5z82a8+8PfGjWLe/t5L6G2lsIiFMQTaVXp8p7cCvVPgzEIR4qnt33pe61NOjledrAleO5oA6fxY15ayR3n2NLu0jhInyOf9kgdzzXnPiiytp3KxRmKR0UIXOV6dOK7keJbHWNK1P+w7t7p7O5e0lyNoWVTkjnrXifjPWr2BpmaVljCg5zyB/jQB5b4z02eGa4gmjxuzg9PxFecNHtUqQcFsD3ruPEerXEsAEzs5fJ+c5ODXDO5yxB5JPI6DntQBu2k5igAYd+GYcA+lVL0tHMu0FZRxk96qJK8WQrkKCMg96nlYMwOMlcnJH3f/r0AbOk3jEgjGUJ3NjgH2FafiXWd9hBCW5hiCR4/Mn8TXHrM8fKqQrHn1//AFU25uJJGXzG3EDjPYDtQBZ0qMyXMZkGTu+9n3r1jR9Xi0TwnOI1Y397IVyvBCDv+NeVWMiwxh1I+fOQxq7ea48sMSRMMp8pBJ+UDtQBZvbqa4vS4lyWOdynvmp2dknZgQ0gXJIUjk98dqwYJGnXIwpDDdk57etayXBZiTiVUwC4JDce3cUAeq+HPFdpaeAtQstc07+0LNTuMT84zznpxzXhGvQ263In09JY7ObJiWTkqPTPevS/D3iaTSHSS3SG4s5PvwyDIJxyDXdWN/4J8WWdxpV5pY0ua4XC7TlBJ2K4+6c8+lAHzSFG1snJ7YpAfXBPvWz4w8OXfhbXrnTL8DfEfkkXlZF7MKyFjJTevOOvOMUAJFIyEgHg9R61LIckEKFC9AMVBkAjGD/WpI3AA9R0oAmSVoxhJmTPJUetFM2SZJVeCc8UUAOLPli+QnQjpmm3OAAuMH2pyZMeSAcknOeaglJLkn6UAIOSAOPen78R8dBwBimH5eB171reG9KfXNajtBmONgWklwT5aDkt/n1oA7P4Rab9ikl8TTIjyW7eTYRuOHmI+/7hR+prvb5Fa2beWd35lLHkN3+vNdN4V8M3TeGYr+4tFtobQCO0tkX5gv8AfOf4u/vWRrdsyqqwq0k05wpAHyL3ZvbNAHET6aZUYwqrK53NuOcqOgrmtX0qW3JkZSo427R2r0FAlsSq8sOXyMZ+laKRadeQulwA0RO0g8EH1FAHh8kT5IO3hs5I6moSv3nbGRxt6ZFep+IPADrGJ7BvNjfjBBLKP8K4y+0Oe1mYvASD0bHQetAHNiUgAYI8v7w9TW9ouqvDOjea4kVvlI7Gsi7gYOfLJY56gdfc1VRgrGQDBxhVHGT60Ae5aJrtvqdsLW9VftTFj5h+65/p0qS9022bf5hXbjAcdMkV4zZanJAAgfKjBxnk1vHxWxjETu7Rj+EHr3oAfr9uiOyhh5e3ch5rlGYEb88AYGWzxVm/u5rtwTlIWyRj+X/1qrP8sboFPbgD3oArSO7jhvkHY1JbxGVBsJUgc8cn3pjIRgcbj1wf0rT0lsPhlB2rkA8cUAW9P1A2UaruPmD5gR0FWLjUpCmAMljkkn17mqzWqExnKlW6Drg0NG0kxSBTszyev50AbWmu7Wis5LkcgEdTzmvpvQNVm8H+C2v5Z43Wa6GUVOxTg8+leA+GdJe9ltLOGIyea4VmU8rzgk/rXffFO+mvdDsF2eTbJf3MBRTxlFXGfXg0Adjo3xK0axE9pBp8EME8plfy1xiRhyx9c1zfjeytNVheezkEkRUEKGBPHXivFbm+NvdbnEgjXJy3GfarMPiQwQHE7qjkEjdgEdcUAUPEttKPMkkTLIccdPpXINgt05J+ldNeaoupy/ZY38vecF8/LnP+ea5+ZDBI4LBjyFfPcUAIoRm2SEDsxFToy4HyndjgZ/SqsJ5Ysp2gZJqyxIfc+CXQGgAmc+aHYZ6j6D2qKNY2nXzQQmAw4656DFOWNsO+SUXpnkMaj4kLdcryc8DHpmgB8m9p2cKqq3BwO3pRIi5YDIGOAep9KJOPkb744HHX3zTEUvGQdu4HHXGRQBI0sgAUYVTwUGAPxqxBI64QNt9GJ+79BVeOH/WMoBI4JIyM/wBaesTBDvOSBkjPrQBqW0q22N7blI5A9fWtC1uhkqjMsq8se/0zWPBE3kkeUrsRgb+vTvVyESCRQYhlRkrjqP8AGgDttZtj418GyW7YbWNJiM9sx+/NEPvx+5714yGx9K9V8NapNpOs2V9bgEwTLKF7MueQfXI4IrO+NfhOLw74lF3YKBpmpL9ohVB8sRPJTP40AeeNyxPr6UKcMMnik4xzmk6ZoAtq2R1z7+tFRoDt+Rdw9TRQBO5EcCjKhipI4xVMc885znNT3ODIFJyqjj3FQKQDnGR79qAFIyw3YyeTX1j8DfAdrofgseINXjiN3qaLKgkX7sQ5UfiQSfwr5p8G6Qdd8VaZp7ELFcTr5hP8MY5Y/goNey634/v7rVZjZjytPkbbHAOAka4CgegwBQB6j4q8bw6W/wAsMUpk+7g4Cd8AV5rN4702eeT7bpqTmZzvugxDEfhxiud1fUn1CwMinaVI24P4f1rir+U2swEJyudvXGPpQB6/e6Za6jZfa9IIdOSUQ9OOADXDX17NZySY3FIzjDdqtfDfxBNZ6jHDGy7JjtYP90fWuk+JfhW6tnN6kJaGUb8x8rzz1oAwLDxrdWrKS5Vjxxxgd8e9UtX8RrqUhDkAkYGBj/634Vyl5C/mP5Z256k+nc+1ZnmSrwdw9c896ANW8shLKqRJ8h5PbNZNzbSrzJGArAbWxnABxjitG1u2EUjlwVYjJ9B9KZcyqCxC5OemetAGOePkC5wSDxyfpSImGLYwMcZHWrE6nzGIIVc8bRz/APWpkgYcfxkYHfmgBIyy7wTgEZKmogQu5lJ3E8j2pwxkhBwTzjr0pWjAYbFyD6djQAxcNJuCt6LuH9akLiJgYzgkYP408oUdAAcAckHioSN7B2GD2J7igCb7fIwOACAvTNb3haaIyEuT5itnJzXMoFZgqhmGMZ9/rWtodsXkYZZCWI54xQB7x8LNZ0vTvENsbuIBJpFTfIOMFgCa9G0m20HW/h74nGuTxWtqNbumjmBAMbjG0r7+1fPul2VzcSxQwRvJLhQhQEkc5z+lM0rVdSutJe21Ayi3W5edUbozHGWPr0oA0td0iwQSrBfW97FggMAVJ9fxrzLXooLO7kii+4QCo79OtbuuatcWsxit8YbqG6jjtXLXcVxuE06li/cn9KAIFl2k7M5PT1pXJZe3GcDvTolDxs2GVlORnv8AWnIMk8YIPTHFAEaq+dhPyE5+n1qdZVYqsqYQ9dvYU6RTtPVlC8jd09zVfbsUlmHYADvQBOZECuN52L91QBTHyAoUnGAfSmk7jnrx8oA+8P8ACo8HOG2qR1FAFy1txI4KHAPr2FWxpzAfJgDd8uR1ptpMPKKKFYr0I7V0dpcCSKMyxogUjBHf1NAFC00jzScKzNgYG2um0nwlPNLGqQ7Qx6nAC/nUthdsA/l4jCHKuBluP6VZfXpIlG2TPcnNAG/b/DXeN0ksRJXJAIxWXqHgpoCGa5iKA7enPXoD3rOHiecsV+1EOVyOScU9tcknQ7ixAB4Y/p7UAXNP0W3hvA1xIFRH6enpXZfErSLXxH4KTycEW1vycZbePuke3UGvO59TkWJWyBIBt554PTNTaV4vu7ecRBw6A5cHOGGOcigDxiRdjFSpDA4+lNxjGa7f4r6TbWOtwahpkPlWGoxeciDojg4dQfr/ADriQQVwRyKAHIWxxn88UUiNgYNFAEjL+6yR3/Gmj5UbkdOQRmlnJZt44U8Y9KjH3QB60Adr8MJBbXusXpI3xWDwoTz80jKnH4Fqta3NtUbZUkwCF3HG72x27Vn/AA+lAi1SAlvnWNsL/ssT/WtKez+0TL5m4qD0HYcUAYa3t3ydh2+rHj6iqN79qkwzfdAwT3r1zSPC8CWP2zUBsiUfuozgl/r7Vn6jY2gGYIwoPBCjv6UAecaTePbFMsVwe3BFeveCPiJJZ2zWt6Fv7QDIglb29+nWvMtU0zMknkhhJ27An0rGZ57Xcu51OOgHGKAPdNY03wl4n8ybT7tdFvSuTHcvlCfTd25riNT8IX9sjmCOCe2Iy8sEiuMfga4b+07gREeYA2QMY/WrEGrTQ4MblG5I4IJ/+tQBY1O2SzYlxsYr905IJ9aoyTjPABGM53e1R3GoPLjcCXbj8fxpkR88ALw+eWY4oAakrMcof4Tjcf60uWdNoZQRyAx7etT+UiopBbuOBwaiY7dxwCSMHHQe2aAGK2S24hfX/wDXTogN+xeFAxw2dv4Um1EDAliTnbgdvenWcbPcxjp0Ukck0ASLu3AMSepx1zShRImAwXHOCM5PtX0l8Lfg3BqfhmLU9Zws94haCOTuueCfrXC/FX4TX/hu7e40+3Z4G5+U5AHoMUAeaaLBHmRJY9uQScntV63hksLiMBG8tm4I54rKt5Xt7rysABThsjtW3p+qI7iNQoI6sec+uPSgDuPDaDVL+3tPtlxaYkVkmt+HyO3t3rrviToEGnDR7OzVRcfZ3lPlsGDLxn8RjNed2GrR6Tq+mSxb/PjkaaTnIC47/wCFdYnj21ufC5muPKkv3aREnkUFkTAwFHbmgDgL3SY5L/fcRlkALKd2ATWbr1xbtaYhQ+Y2RuA6n09qbq2tebLIVkZwTlmB4z7VgzO1w+NzHJyE7ZzQAyEqq4kX5vX1NN8wggICQAQMn8q7Hwf8ONa8U6n5MEDxQsciXaQCO+K9b1b9nzyNHlGnbp7uNC+zdksfpQB87IS+4tncAOOmPoe9VmJLEkFl5OR1Fa9/YvaM63MeCjNGVP8ACw4IrK2o+NowB6HpQACUFDuIO3kD3pxwzDghj1YDIz9KFwFyRtUDAwM1Ko3pkE8dh39MUANjWFRhpCC3IwPTt7VcjvvIPySCSMcFRxiqXlKCZHI6H5c5K00GNhnecqMdgaAN231sE7gSpUcZHO3vSNqA2MqvyR35xmsRVjIYHOMcjsfcVDNjzAykgYxx0zQB0UFyg5lBLHgcde1aVvcImGyQw5Matg5HSuQVpFQbSB7GpEll+UqTkH1zmgDobrUC+WJIkk4IznIqGzlJX5TnDcLnFZdusrI+TtJbA+nWug020OVVUyW9s8/SgDe1XT5NZ+FWpzMrF9Huo7lc9llyjj25CmvJc5YkjJNfYPw/8EJP8MtYS9UiTVImiGSQV+UhTj64r5Fu7Z7S6nt5htlhcowPXIOCKAI1brkHr60UgXA5PXmigB1wfnIAx7ZpoHqcDH50SE+Z83XvQBwo4wevNAHRfD058TwQZx56NHg9zjgfpXpbWiW8wkVT8vHrurzPwK4t/GOhyzDEYvolbHPylgDj8Ca+gPiJ4XuNLkdmVfs6scOCMkbu35UAcx/aFw6mGdVYBQFAGCB24qocNO20SFv48xnGB/nrVVbiJT5nmSSNuAOxC+RnAzWxDe2iowC3WMbcmMk9c8fnQBkXVotwQtvbnay4Jc7RnPAFc5qGiXCFnaJSoGPl6fnXo+dPMSri4UyMNxNu304NXbfS9IvbY202peRIeA8kLfLxnAFAHgt3pksLZRDg9DnOKqSxvwzAjB+Y46V6z4q0Ww0a7+a9jmjx/wAslY/TiuX1H7HIisI3LMO6cCgDg3T5+WHJ4OepqVGdH3KvQZ5GK2ZNODS7/Jdj3GABWzDo6TQqxiBJGBjgigDmo3BiAJG5myQvr9alKYU8fMOcY7etTahp72dwAqExjO3FV9xUkks2fbtQBDMm08qV/HvT9OOb63UsR+8UZHpmmy7nIA5QEkkjAUUyywL6JpAAhccsetAH6BeHrlZ9K0jyR+6a1jAVCQAF4H4YrqbnT7TVNP8AIvIxLG3QMBla8D+CXipbuCPSZpg0sC4VS3PHT3r3vSZnZP3uATyR3z6UAfNnxW+Du64mmsIRGGycqOPxrwTV/C9/prsJYWKKSAynrjviv0Q1aGOeExSqGjI3OD3FeceKfBNlqLq1rEofOcMvBHpQB8RhpmhYyO6Mq4J/iPsaZMDEq7jhcfd6/lXsnxE8AyaXG87RKmGKl8HHPQ+lcV4N8Kza34r0zS3RR9qk49xjNAHN6P4fvtWmSOGB9rHqBkCvefhh8FfMmhutaiDKyknr8p7GvWvCfgXT9DWNPs4ZwBuwCQewz6V6JpNgkUY3RhMAfKOB+VAEeh6FZaPYrDbwRxBVAyowRgetRM6WtygVvlDfKF5OPU+1a92cQMCT83FeWfETx3B4bgbyJM3cikFeu09xigD5R+M9vHB8RtbWBibdr2WSMIeAHOelcOUALFTnoAwFbvji/e81hrp12yTOzkj1J9Kwl5LKS7AfhmgBSd27dyCDtOOefagR4GEODT2AwCUbb7fyqOSTGGYfdOP/AK2KAFmdhMhDFjjsOlV3yrEkHcG6jAH40rbicltit3amqrE4yAqnOW70AOQHOcjB7DnPrVi3UMoMgBUA9DioixK7ty9z8vaiOfZnp/tD1oAv2+n7wgkB3HjINalvpkW1PLjZtv3gOxqPRb2FGTzCpBBO1jjntXV2moWW8+TFCGC5w3I+vvQBn6ToUtxLlYGcj+6OnpXq2heFrPQhHdaoyGVFDBOCC3v+mK5zR/ERtYsJBCoAKkqPvD/Pen6ldXd0CEZjEc8Dr6jk/pQB6l4W8WLc6usE8xkh3bCHAAX6Cvl74u2y2PxK8SwAKD9tdhgcYb5v616N4WiuF1u2Eiu5ZsMWPTPTpXnXxgnM/wARtZk27W8wA855CgUAccPeilBIHVTnnpRQAs+7zDupoGSOoz0p8py7cZJOc/0pu4nAPPbmgC9pW6PULNwCu2dD16YYc4r7S+IHhWxgivNXdZLmUyAIkrnagPcD1r4t0qJ7nULO3QMzySoiY75av0E8Wac91oUkExiZSoYTg4ClePmP6UAfNV/qstoxEUMSD7+1IwD+dWNI8TTE7vk3544B/GqvjDTpbZ5GaOZVBKhsccelcU1xLayq6sGLfKF4wP8A69AHrEfipjH83BJyQ2Ola+jeIBNcxCaFJA+SEMYPNeMWeoSCUtN8nBJJ7j0HpXcaJqMNojXc244UbFUck9vqaAOl1+W0W5ug0UXmS7ZD8g+XIxj9K8r123n8wtGCFkGcAdDnjFd5HFNqN7PNcLMZLgqpXZlUHYcV0Nt8OpryB5r2VYIApLPyRGvt6n2oA+fpUuY5Tl2+Y9F5J/KtzQI5VlRC7ck8dse9amhWFnrmvR6Zot5FLO8rQwQ3I8lpMdwD649a3bqXT/CBmtIjFe6mQyyOvKxk8EDPUigDhPFsQEUhB3OCQo7j2rjDLlwGkJx17fhXXeIblWUgsu7OcYIx7njmuP2kszIxC4JJPWgCZgQu8/dyAVDd6hAKPvIJ5xjHSpY4WZt0n+qHIOe/rUwaJGMTAvnoB0z6n1oA63wZ4nm0C9jvUCySEbUO7G0k4yT7V9a/C7xdDqOmQm/ugL75izE5DDsK+F4cRtkOwVeNpB4P0711/g/xNqGmFY/tEqJnJUcH60Afel9rVlbCAXMiiScZTac5xU1rcW94JCZEbaSxTcDtA65r4wsPEl/danNeXF3PJCiqiRMxAUA9vrnvXrnw38aJpmm6gJmjeXcSgdiCU685P50ATftR38dl4As0SZYnur75Mc741jJPP1I/OvEPDuoP4Y+KXgfUb9JIrNzFIWbjKN8u7Pp82aX4la7ffELxtIql49NgUwW/mHCrk/M35/pXb/F34caxqHhzQbvR54rn+zbQW+VBVhGFGD+goA+jte8R6ZoB2XpGZRuQK3+sU+nrUWl+P/DV7ewafFqMSahIP+PY53qB618v32t3DaDpLazfH+0raERpuyTJjpyeg7VCfikLbTSbPSrRdXbKyX4X94cfd7UAfUfjbxbZ6Dp8tw7EumBs6FgfT8K+Q/ib4zsfEWvXFzaO7QsSy5U8nPT6jHSuW8QeKdY1lGGrXsz4yzfMSW44+lc7OLmVVYzoc/mT7j1oAiu7v7W5Kg5Bye4X2pEh2uI2YKOhI9aIYUjVd7N5h6juTVmaLzBvP3euD1z9KAKr5jkaPklRggNmrNlbzajIkaIWJ6FgMAVWcbSC5w7c5zgk10vhcNIrAEMSvr6GgCq/h+Q/NMVZcEbV4AqpPpTQMUXmJuc4zkd8V614d8NQ+JJWgtbtIZjEWjt34Ejg/wCcVmal4Z1WxuHtr6xuRJEc7fL3cex6YoA8xeyj6ZCkg8g9qqz2UqEfLlTycLzxXeatoZtbgWlxBJb3Lx740cbSQe+KpWMDXMv2eSPBUgb84xQBxBUggngE8euatwzNCybm3c9e+P8AGutvvD7CNy0YwCSGXHt0rn7zTZbQIYwpjPXPbHvQBZtr51dEEzAEhuT94V6B4avXuC32ciUBcNGT19MV5akyuvlmNdyt9/pXVeC9US11S2a4O6MOPM9xQB7B4Xt0mmN6rKyxcupXDJ6ivCPiiySeONTmiB8uVt6nHY16sPE2l3PiR57JZoEeN4pkbhZOOCcenBryT4kGM+K7gwldoVRkeuBQBzIX0NFLG+AeAee+aKAFlbMmRx9KYp+Ydf8ACnTqyyYcfT6UnBXgYzQB1/wsmt7bxjY398jPaacTdugx87L91efVtv616HrXjbxNqd4Z9TvZIlk+aOGFyAq9vl7CuX+HOkLD4dudXuslJrlYEUDOVUFmP54FQaveS3NxcXBU7ySV4zj2/LFAHXaZ431aMPHKy3NlJw8U67gT/eHcGmyaNpmrxtLo1w4vCWZ7SVfmHP8AC3Rq8wXWJ4pJcEENwVfr+FbWn6432uOe3ZVkQ5AHBPHT3oA6I6Ddwzr8gKr1Qcr9T3rd0izMbrdSMCc7VX7y4qlpvxEu7eYGS2tZlI2srDOR6e1b97qmk+ILITWFjJpZbHnIjZR39VH8IoAgufGVxpNqwtivmybidvRRnjn8Kr6F8XNY0sSwOq6hYuctHMSwBz1BFed+KFuI9Tm2swjBwvGc/wD1q5yK8nSTag8t8YPORQB9GeH/AIj6TqOvW19q+gWh1C3BFrLEApjDZ7+v1rz/AMT6dJbazcSCSURTMZImcfeUnjB9e1cvoFyzd8cgkAc/hXrNvLDq/gXULW7GJoP3sM/9xl7Z9CODQB4xrCSRSYlKtExO1ieT+NYxcwyOpzt9+v0FdN4h8yK2yjKwyCAy7uo6c1y25ecjqDnjj8KAJoZPNfZtO324A4pN0sZdFJMZ4wefyqJnbK7VwwGOO2exqxBtMmNx24ycfyoAs264RY5MEY645/8Ar1dt02/Js3hhtAxnH41XtnClThmIJ69hVgv+7Vd21cZBXjHPFAFmG5mWJ4QSYi3AB9K1LK+CxpHK0rlJFCnPQd/wrKt4gjFxuPH4Z+lXUUsxYoc8ceo+lAHe/EnQrOb4c6XeaZJtmt5pHuJVwMggBeld7D8QLS3+GRXbM08tulor5yN4UZNcTZSl/hlqtp5ZILRx7sdzk4HvXN6rMbfSLPTUI/dFpHdeu4gDGPwoA53WtTn1KcvcLk5OwdeKxXlC4gCEqT/rCcHNak8btJkdPTr+NUJlZQ5IJAGACM49ST60AU5XaRAXLHbgAgdRUc4Z1kWSNiy9D6GrKlgFAKL255pJCxRgC23HUnrQBQjbz0ZpCNy8ZxyMVI6M+07gc45OePqKbDzICzfK4+8eopzsRGHzy2e2QtAEdyN4JcAsuRux1A4q5okrQyoRuUZ4K+1EUJmgaMgImMlvr603TwS21STGp69hQB6L4X1ZtM1O2vQrNtYMeCCSDx+FekXnj3+yPFdhquj3bSW96CLi0m52HuAehBrxy3uPlOeU/hx0BPX860UCztEZov3aYxnnP/16AOr+KKXEniu5S4LNNGBv3DlifmP5ZAxXnZGJ0aLdHHkkjHU9K9G1eVvEq/2lHuNykQjmGc528B/fjFc5a6UNSuGW3Vi+7BUHkN6kUAUmuXZFWUnCjCg9R7GsvUbNpA3lq6KedgFdyvhO6aVVnQI+7O0dfQn2roNG8D3OoI6w288pUEfulLAZ9aAPEX0ppY8BNvOTyOe/4VSuLWeyuA4Hybdygdfxr3S98EpBq8WnOr/bTgtEgBKA+vp2rmvGHgybTpGcxzfZuzSRlc/5NAHCaTNI8oLnCsMEEnLVg+K5PM1mbBwqYAH4V6boHg7UL+dEghCA4YB2CkgdSAeteV68zy6xeSFML5pA/Djt9KAM4dKKdjk46fWigBz7dwJyD/FilYDkjJIGMikcNkEhuav6Fb/btYtLYq582ZPkUZzzz+maAPeNT8Pz6R4J8N6IYn+0Pp4vHHQF3O8qD3IBFeY6laTxhUkDYb72Oa9c07xNL438RR6E1p5BZmNlIQSUZFJCn2IGKy/F/hm8+0GOGzlt7mMHzIyCQeOooA8Qv4dkyDB2YyuRg/Sqn7xZN6cPnJOewrt5tKaTcJImK54J4yaiTw/JNAcRuSOAAOvrQBzNjdSIRtduDgYFddoWvtZO7IPMV12Pu4z74+tZ954dMHTdFIo3bSuMfX3rEvLG/gJby28v+8vU0AdZrMsN4/mA7XjGAqHpXK3KhrxSGRlyPwqqbq4ijA3ssmBtPt6U6N8MkrsSxOG5oA9B8FWgnkUHAHd/7tdJ4iuUtQdNsQRFg+e4789q4rQ9Sl05xIjoScbuOCMU3W9bVrWTb/rSuSo55z69qAMLxDqAluGi3bo42PBPNZNxI6glHHzdgfanIyZywLB8gLnoetVZpFMjbUPPGe9AE/mlmBBO4cHI5q7bAK2SxbHILDqapQxgRErgyFsHPatmO3CRpmQbunPrQBDDvT5WQKQcnPGf8KuBFk2thefwA/H60zyQ5OOcjGfpRJmKAbY9yqM/n6UAX7PebhIxkAHIzyM1qxsfn8wgqowDjqR/SsbRSJ5XX5gOgHp7VpLKI0RJhtA4Oe5AoA9m+E9jHq3h97R5EDbZLlmYZCjgJz+fFeYeKp4l1O+WI797bm2AfI2Tx9KuWPiq+8O6NEmnls3MipIxP8K84Htk1U8X2Qs9cE8G37PqkYulbHI3Nkj8MigDAZiHcx9xgEjIx34qjcHbG2xyScNjGMY7j61uNZqmDs5UEqfbsawb5hFdSLkLF95fr/WgCn5qKys+3cRwB/UUyV2EI2t8xGOSeh9qsRWweLzEITIJPHeqN4vltlM7gNuD0b2oAQEFCAAVGQM9yKng3Lb5K/LuA+ZcgD3pDFJ5SkxlFVN4/wD10vnPFCRIQN4zgdR6CgC5EgSIiPo55DNkCoUQxStl9y5wAnp7VPbFHsozMVYhuB3HrUaGI3AHOxj27UAaVoLghQqEoxwpJ5NakAuPO23USvgZABI/LFWbS2RYIiApwRlTwfqK3tH0qDVJRFFK6XLk7FHORnofSgCHw1dT2WtW8icqkgUK/KlTwQR6YzzXsjfB7T9R1aS50zVJLZ0kJWSA7ipPzYI9ea57wT4C+16qsl65+zqc4xwcf0r0F9YsfCsuqXj3TBpokDRt1BGf6Y4oArX+kW3hy1a4vbhtQaL5EkuMKJWJ4XA5rO8afECz0TRoBpsaLqDKMiBtqrn2715T4u+IF14gvxPdSlNPtyRbxjjcf7xrzrxFr0t1cmR2ySvCgcj0oA6fVvFWrahqk0096Y7h/vMjfeXPANGl+PNbtozBdzNdWxKhll+YkA56muFSK5lTeQ6qTu3dsdxVqecttRFJC8Kc8jI6kUAdR4zm1nW/F8vifSi40+1iFxt3f6tUA3Lx24/WvKZZVmlaRlKl3L4B4Ge2K9T0jUINP8PeIIrm58oT6fLFHkE75DjA/HmvJOpJ79TQA9WIzgj8qKWMfLzj8aKAHKWbK8/hivb/ANmTwVDrHi2613UTEmk6UhUljgNIy4HPtnNeGrwy9x78Yr2vwjrUnhv4YWdpbSGNtTke7uADyVDbVx+VAHqttJ4b8KeKpr3TJ1kuI3+T5MhCeDg9zzWR448aXTBb60uHF0GbY8ag7QOxBHTnpXl1rqHnxvPPIQZCSWLfKOcAmr8tvKwtzbT7t3ROTnj/AOtQBek8ZGVI1vNMs2uUBJnC43N3J7fhUVn4vuILhSumWLQfeG6LvzkHFczf2TmSR4gVweewrKNxNEu3c2Q2CBk0AepXGpaP4lnLXdmNPuyAGmtpMq3sQaytc0cWtsWsbiO6TGNuPmIz3rjbLUjHLkFck554z74zXS6ZqCTkxO4jdjw/UH60AcXrmlyvLve38tAOCAKw9UtGtQrB1Kgj5Sc479K9x8RaSlh4bjvZ9rNMfLiAAwx/pXkXicIuAcEseGUAUAZpuHVNxYkAdFOOtU5J3ZWUyFmIHLdh6GnsQCIlQYPVjUAiaUuI1zwM4HagBC4O1dp7AFfalVUec4AIQZ9CalCMHUyKQFHII60zajBz90ZHT+VAEtrKEufnXIZs7e2a1by7RnWOBEUk/MQcD6VkW8ZeXcmSFxgDn61duYQwDJjAOT60AW7eRlJdSCcg4XjFTsDOrMwG4Dgnj6VV08EOFbBJ7D0/pWjcg5ZApG/kj6D09KAI7bfb+USi4ySDkdauTB5ZFkXkD0bue9Zk0wQrl8xp6r6cf5NTxXz7sAfK+OFHI9KAOs8V6XcW39i24JVvsySAngFmOTXX+OYbW68K6ZPApd7CURF2P3gyjgfiKzbjxJa6ppeky6pbRyzwhYVeMbenAyPpUvxC8TWi6RZaPY2qKzyLPOytyMDAH86AOGn1AqnEjKpBycZHHoe1cpeO8ko+bcSSRitCSdURlPzK5JA/w9aooj3DMwwMnIwOPxoAdDNIi7CMhueTkKfWmzsW8tJCHHB5/rU6AxLjjcxI4GcmoZI1YhpjtR+vHp/+qgDVhnjWzaMcheNu3oPXHrXOyznA35ODndjqK1ExJCVU/wAJZWI5J9DWUEDKy5bhTtA6UAadjOPmhByWHf8AkaltFQ3qjLsAegI6j2rEy8ciy7ccZwOlacV7GWgYAB0GcqP1oA7WwZQZVh3H+8WHbGO/er2l2epajqcMfh64EOoygpEz9N2OufXHeqGkTxzWcTI2XYktxjk+lemeELXR9D0j+25NRhe/lRlhgBG6M8jJ9T6UAZuk+Ndf0DQI7K4uvtuqwqwml3AgKT8q57ketcT4k1y+125D6pfbYVJcxpnDH8PajWJlR55VkZoy3L+vtXFX968zk+YzAE5UDAINAFjUdRe7JhhyEHIDDoPXFNstNUo7vKUlc5JZuo9jVIOkTljzIy8Y7e2asx6jGGQucrnAJ7+1AHQJpN2LaIlz0yNrZx9D61EdCnYSsZTvzlSP89abaa0oVX8xlA52gZz+FaE2u7Io3/d8Lg4HA7UAb9hFFaaHeRXSIy3VrJaxKVzmQoSP1714oxxwcccED2r2Hw1q0U2tWB1JPMt1kDIp5BPTOK8y8XWB0vxNqVljCxTsF4/hJyP0IoAyw+BjatFNBNFACuhVtvPtxXqBIk8L6CBH8gswpOf9t815tOgW5ZcEH34xXrPhLS7jWPhlDqNpC0z6bO9rNgZIU/OpA/OgDlLi6FqBuxtGNo7Y78VNYeIm3wtExR0O456AYqe90l5lfzgrDccMTznPas258MxylfLZoioO4HnNAHUtqttcRMJWBbbksnUfT1rD1NoxONnzZHTHHSuevdPuNNZlSQtggIy8Y96om4my4aZ2IHOTnP8AnNAGlcTbLpQwUqcBipxjJre0++UiLccxseDj06Vxckg8kDJYt0z39KnjeRYxtYYxjnPB9qAPQ7/V5ZoFE9xKYUbKiRsiP1xXEanMb24LkExpyO2foKqNPKuRMWm3DI9ef5VJbrvOUz8wx64oAkttOu7y8htrS3Mskz4Q/wD1+2Peu5OlaTodskM7m51DbulEaEqp9Pf616Dd+DYfAvw3sZSJJtZ1VRJPIox5atgqgP0PP1rgPkaR1uvkkHTKkj/A0AYXjWTTZEtJ9Pgmhk2kzo64VjxyvpWDPZBtz28ZK4BG7g575rvYri1tlyZFfk/Lt3fjirFvrMFu169poti0tzCYZrm5Bb5cggqucA8UAefafayJMryROP4dmM4/xr0XTvhvqFx4eOo3O+E7d6xEZby8dawYdYOngzWoh8w/d+TO0/j9K6IeNvEeraNcxWU4F0wx8wHK98E9+elAHLW9gYJnwjHB2qAP1pmos+FXyipUbRkD5gK+gvhh4UtdS8K2a65bfbNTuSXZo+NoBwM47e9eVfHXw3F4a8Q29pETFbSRlyozwQeeaAPO1SVlO6MrH1PtU0UJdwOVHTPqPSmwu5xtZTGBhQw4IojdxJ5jMvlkYAVfz696ALN4switYbaSRVaXefw7g/Sp9TDyozne7MxyX/zmoo2iLoswlwCSMHnHr9PakuQSGKyo0KnkDPJ96AM1/wDlmGyONqgDvUSDJfOVKjHynIOK0GeIqEQBh3+Xp+NQSosfBUqi8jac5H4UAPa2Yqj9Fxkq3XFV7xCBt3EORwp6H/61axRrowxqjj585ByST6muh8MeBLjWdWt7RmSGOXJVncc468HoaAOEtZmRA5ICnKAY6euKbgLEzdFHIB6/h717xrPwBvLGxjki1G3V3AZYpSec9OegrzTUfB+rafdLDc2QjRjhXY5Vu3WgDjTyp242bsjcOgqNgQxYEYzz7+1dlqGi6Zp17bW99dk3TrulhiXfjtgn+E+1TjT9Et51Q2V5MmAcEYIPfmgDl9J1OaxYmMnaOxNby6+su1vJwccAHPPvT7nQbG7d30tZCcZ8pzg/hnrXPqs1pKUKqH6cdR7fWgC/fX01yozmNGyWAPH1+lV7W0884HzAjhsfdqxpMS3lyYiG3sM7SOtbX2L7MciLGB95R2+lAGC+kybCDyg6E8YqMaGpw0pEYPI79q7C1sWdmfbI23K88g8c4ra0jw1d6jcIixZQjAYYyB70Aecf2GEw/wBpKKf4sdPwrSstDRyhRpHwdyjGQw9cV6nFo3h3SprpNWU3CQjbGFJDyv3x/sisi48YQ6YGGjaZBaKCf3p+aQgjpk0ATeAvBUlxqdpc6qDBYpIJCjkBpMHhVHue9YH7Snh6Ox8VWmsWgIg1RWyn9x0IBH5EVQvPENxqOoqZZ2muAR8zH5UHp/8AWqr45vru68I/Z72VnFvdrJDuPKhlIIHtwKAPOcCMlXXn60UzI+tFAE9yWaRd7Fnxj1wK93/Z68VW/h3wx4nF6zNHGUnVY2w5c4VcdsZPNeETneoOQSOB7iul+HSvc63LpyEKt7GUBbpuHK/qMUAem6z8QJ76+kkbT9Mt1OSVS3XceeCT6965vVfF0jRsS9umwfN5aqDz6j1pL/w/KHaG7t3SUEqQwwR/+usOTw3E8rAxSD0zk80AZOray97t8gFQAQMHGT649aykspyok9RkjOCa7a10S3t4yZURJAAPmHJP0qHU/IgiUwxLxgMMZ29s0AcjJCSEDDGfXsfalQHggnrjcB6VJeOsl2y/MVLDnGAMdac4ZSRFsY4zjPLUAR7is2Vb73U06FjEBJES4zgg8VG+7gHJHVsnvUyxsy7VRjgFjzxj0oA9Iv8A4ueJdW8MDRL+Kxlt0RUWXyj5qkAYIIOM8CuXHiC/BzPaPIG4JKkdO5ql4aaN7ra7gDoNxxzXa2ZhlYxGUq6k5Oc5/CgDmY/E8i71+wj95xlhnBHfpWTqGqX1yjE4jQ/whc7hXoEenx3ErLBJAwII5bbz+NSXeiSxQRtc2gEcgwJWxjp2I96APLrWGRgyOWdcgjk5zXaadZXNjY/aImIlZA5XqTimR6UE1KDLp5Jb7jcYOfX0rormW3tLe7nmcJAkRyW5BPYD60AevfADxJNqHg8R3MTqyyyQTOoCHIwynP0I9q5L9pZ5by10meYqXEjxKFwWwvUkjtmsX4a6rdw+Br28mV7SKS5xb4yBICOuO+MYzWh8WoLaTwHaXfmPJdpdLvmbklWTkEf1oA8WVHXaku4YyAwqzboXRllZiM4B4OPwpj7FKiVyIsZJBxkY6H0qJbh9rFT8u7qOce1AFtYfNjfaCqxL94cHrVd4CyEguVB+90wP5Vbimb7PcA5KpzjPJJqjvnD7i2STgYGKALKYjgWMfOoH3wMMPb3qC3UPcCNx8h+Ydxn8O3Wrlo8aSSrcndkZwvc9h9abpKG81eCIrjzJAg2D5m/CgDqdDsfMngtI0OzO4Hbngf0r1L4i/D2PUNA0PU9J1N7Cez/1qZ2llJDZBHesXw7ElrdH7ZLBbi05YSHBGexPpik+LPiiS31G18PadJm2KK7SrJuUkqD+IGaAJ/FXxJ1GTMFk4KRDb5rKNzY4PsfWsCLx5rTov7+K52YKQzQKVNYRsTtQSIS7A/LjIbjtUC6TJsJhIBxvOzJoA073UdPupluIdPFlezSNJeMvIkJOcqTyBk9KrzwxysSJJC7DaquwIUH3/CqcM8cjNHcIu/bjDdc1o6bHDKPlGeeSOw9waAKi2snnKVcDsAnJjb1FZXjm1EN3Z6kv7s3kGZE2jaZFJVz7cgH8a6iSSCERvGqg52hGOCT2rE8ctF9j06yZ9/kK5cg9ZHbc34ZxigDF8MXMcl1gkQzbcByQMH1yfX0ruILuysYjLPHLczt1iZtqjI6EjrXlGwQOFViCx/lUralfRNsWWQqByevHpQB67b+K/IyttpljG7Dqyk4HTA7fjTJ/GuroWLXkMRBC7QFxj0wP615E+o3MxYGQnaPXn8KbAtzdyCIFmBOT8x70AdbrnilpZ3lM8rzEgBQB8vr9BWEBe6hcuXdo0Y7cdM4963dP8NRRqszK00jdM/zrrrHw5Gkby3CZKAbSo+8T2x9aAOT0nS5EkESR4PTdInH/ANeq3xGSSz0bT4JAFeaVmZRyPlAHHtk16DpOllb7yJAV34BXJyoz39K4H4zX8E3i6CxtNhgsIRD13LuPJI/l+FAHndFT4ck4UYBx0ooAi3BhtPBrX8Ky+TrtuwBBAOAOpNZDcKACMfSprG6a2vIZlzlG3cHFAHper65dzTmSeQsgGCp5AFZ7+IhH/rJXC4OFB+97CmwPBd26yKVd247jb61UGlR5MgzuyRuJH55oAr3mtF9rKCH6gN2Pv71kNLJcmRWciPqxPFasmn+VIPOR8DnpgmobqANs3LiMkA5GP8mgDKZGG3C72B+U9CatwW4nbkESscBVJH1JqzaW5NxPIrBdityevHAxW9otg0UExRQST87sOnv70AZw0KNbRXuJAshBCj+HP+NR6dZ7XaKcjerAbMYJ9/QV2uqRR2Oi6fEi77u6LXEkjnlIxwgAP3c8nPWuBmmlW+kMA3fNgtyRigCxd6POC0ka+XNH0A4H4UW11qlhKJpUEigAeYR09ATV+PXXjttjBXJ5Vient9KvWqG8UMoMbNne2cqR7UAZdtrSyNJ54MDkHK8j8R9a6PRtSlWzZWLNCw/1RPGPU+h+lZRtrWJnnEZABK+a4/lXQeF9C1DXFVEjay0vftl1a6QrBGMFiQDgk4HagCbxDpDaZp9hqEpjnF7hraFDmWVs9FQc8fTFVrvSp0iS88UxpGsbB4dIX7z9wZT2+nWtibUtN0K0W58NvLc6gpMA1Sf5pSnT5VPCKR6c1yeoXEpmVVunkuJHJKFt2T6g9uv1oA7HStSl1fWI0YRyIFwtrGuI41xwABwMVL49lmt/A8kKx4Es6MMLkYx/Dn09aj8Gw2OisFvnd76UqohT5hDnksT/ABemPel+MNpeaZp2nQ3N6bqGUmaHgKQpPCt9OaAPJpYN0qeUw2/xZyQakSOQW5ZFOwnLhcfn9Ke0zNLtEe9umwLgN9PSoYBGjKWlcSDjywcH8T/hQBZMEr2z+QFMakAyggKq4/WqsQaIEwEuxGG3AAkf7I/rWuP9KsWaRhbSbseUBhHAHb0NY8bNG53F4tp+VW+8fegAtcwzsYH/AHhOcEA4PvXZfDy1Evja0eIhmT95Ko6dOoFcdvXcrHMZxxgcH613Hwcdf+E+sRHJIvyOoZT8/IwPYj29KAOr1HSpL1rua5FsLW8YKVZv3rj1HpiuD1K31LQ7+00/WohLZFsWd/twrr6bq9i+LmkWmi3C6hZ3LWWrKgjCwk+Xdg9cAfdbv6V55ealf31qttd395JbKciFrh9gPrtziuTEYyGHaUk9T38n4dxGbwlOhKKUXZ3v+ia/G5DaXDPORNJgqcqWycD1r0TwfNaSXPkyiFW2/wCsbAD5/wA4xXDCyvJNEh1EWk95ZQXE0dzMrs8kCiOIocEk7QWfp0zSLHJ9naaylF1bM2VMZ4PHUeh9q6Kc1UiprqeTjMLLCV54ebu4trTbQ9M8TaH4UkVZtRa1tJsYZo2Gc+y1wBtoriZrPw9azTs7FUIGWYf5FJBatfwxm9aWSBTjey/Ov+9/jXV2kreE/CksllGouL9jDDKR80agcsp65qzmOPfTZ7XVfsOpQr5pKh8EEpnnH5GsrUtGhudVlgVNsUX/AC0z94+hNdv4f0ZbPRZtZuyZppCfKRjkr6sfeuSlnYifeDLGSWEajjnuPegDmtS0BfKeRQBGRujk6c/4ZrmZEkKsG4KA8+lepeI5bcSRRWoLWdrapEzYIO7ktkemTiuFh0q4uI5JIz/o75ZVUZIHY0Ac9afv7lISF+Y47jFdlplhGQkaxqvTe/qfWqLaG3+stZA42jL7eQc4wfSm2N5PZ3PlXiycH7xb5c0AeoeH4SgUPDsIwMkDmt69kW0iWRl2mNMt1HXpj3rjdF8SeSpVlEsRwCzHHB9e5rp/tlpe2ywrOHVgWaQnlPcD8OlAGDquqra6Ve3aB43WHYjMeNxOM/XBrwfUJnnvHkdiz5xk9/evbvipD/ZvgiK4IWRbu4EayeuAT0/nXhOSzEseTQBftVfyuJFXnkE0VFbyHygDIBjgUUAQFgoYADB4470wnHYg9celD53cgD3HSjqcHrQBasr+4s2DwSMGHYjIruPD2u6dexC1vSba6zlXbGxhjp7V57x2P51IrbTuDDIxjPUUAeoyWC7PMWQFTyd2OgrF1gBYzIPvDnLt8p+nvVbwzr+nxW8kGqecs5+7JuLIx9x2/CtEyWV4A1zeRMz/AHWLYx7fhQBQ0ZcbjNBvyBiSToOc/wCTXQWFlc6hqttbK4klmcLsOAFB54rDmv7K0h8uWSOUJwAjHmqK+KZLPULC/wBOmMVzbyM3CZAHGBz14zQBs+JdUln1GeWIhyw2KD0VRwP0AqDRrUfN9oYI8gzuYZDDoSKy7rX7ea7doLfcHYlSw5XnpWp4dXWdc1KCPSoYkmUhBI4BAH06cUAW7qO3tZhII49rHHmnlSemQfStrw74T1jW/LuIY4rXTyTnUL9vKhHGSUU8vx6V0VpofhXwPor3OshtZ8QK+IknO63hOd2VTp37963viva6hrOheHPFQuVGnG1jSa1ibH2djyPlHQNQBF4U07wra6Vfanplnc+I9U0+NnQXyHyicjkRjgAcnnJri/EXjHXdftWs9avSsJP7qzQBFAz93aOABVn4V+J4tC8SLfyyXC2TM8T26L94Nxkn06msHxjYJBq128LsyLIzq6E4wckf/qoA1TdQR+FoYfssO+OP5lhzuHPr61ymlbIbotGwVX5eJz0H19ajuNTjFikML7VPDYPJ44+pqvC1sWV5D8+MlVypI7ZoA7Xw7IZr+JhdLEqfKFIzu54rZ+L00N1pls/n+btUL5K9c+pPvXJ6Pezw3EcUMcf2ZvmIXkjnmt7xvcW8vhKAW0axStIF4GSQPX/PegDzzO6FMloVCnCqPmNNsolY4YhGAwGbqPxqSXCwpFAcv/y0OM0+KKRTHIoBwMlsZ/L1oA3LyzRPDIM2TJ5pzIiYOPeuWnubpprfTkgF5NcMqwhM7yxOFUd85xxXoN8U/wCEOgUNuZyWJxjp3rzHWJZYdTtJrJ/LuY9rRvbsQyuGyCCOQc46UAd14n+HHivwj4CtvEniG3tra1nmFutnJK32mMtuwWXbtHCk/ezyOKofCnVY7TXhqN2haO1IYKvLFj0x054/xr1TxzPq2sfsh+GbjVJb6+1KTU2MslyzyzMBNcAbi2ScAAc9sV4p8PTbCW7F0AcqACSQB15yOh6c0ne2hUOXmXPt1PS/Euu3niPUze32F2grDEOREueme59T3+gAGHd3It14Uu56IP8APAqCa+S3DIW8x/4CONw7Z9Kox6ooZlmR1Yj55BxuP936V4tPBVK1Vyr7fn6eR+nYzibBZbgIUcqs5Naf3e7l/e8vnta/ZeGPFl1otvDdaYhlS3uZGu4iM5R0iABXvyjZroL8aL4qB1LwPH/ZeuOVEulouYLpi2M7Tjb6mvLzO1m5eKXZ5owGXv7N24963fCh08C91G4uG02+t4i8BjB2SPjgZ6rk17FOCpxUV0PzfF4mWLrzrz3k7s7fSNctdG1yPTvGNrLoWuI+F81M2030foM+vNaXxdurC9vdFOmXFusLWpEaxSB4y27LdO9cV4R8RXeu3cekeLYm1fSJZGe68794YVA5kVuoIHTHtVKW20fSG1C08LtcyWFy+fOuwpkEY3ARocZVCGO7n5uAeBzFevChHmkdWVZVXzSuqNBer6Jd2dRrviNJfCdtYWwMN1EBHKn3ffr3rmLDy5ZjImEWKJpTtxyR0HtyafrmuJPolt9vgd7i0LB7iPAaaE8/vD3dTnDclgxB5UZz7XxL4fXQNRt7eSH7VdKoDSfKUAOT7Zp0qsa0eeBlmGX18uruhXVmvua7ryKOrPcLbbcPFK/DK3OfU/zNa1okbR26weXHKiDCfwsMc4Fc3H4htYo1EkivHuwVHb3BobxLYoEkgbcI2DBSe393H9a1OI7lNOPnRFIfJlLcjqpp3i3Rbc2cFzCIRFIdkiq4dVkHJzjlc+9cFrPxN1C7aQW8Yt48FY0U5VRzjrWT4a8YTaRZajbTwR3iXpVneVjuQg5yvv60AaRtbqyuysGZVxnbjgj0zWzY3TRzLJE4UgE7QcqcHnn+lZEHibT7ob53MAbqnOc49e9atvf2cNg9/K8BtQ2FBI3u3fj0oAX4yawj6J4a0MGQPbxPdzbj/G5+UH0wo/WvKWyW6DjsK0df1STVtRkmlYhSeM9fxrPbH8PGKAAL7NRTce4NFADpACu5c46c1HU6y5idCOOtQUAKOppeCefwNKV+XOG+uKTqKAE60E/LjsKVBuIAIHvSEEdjxQAHrzSVJHG0kiLGu52OAo5zXoXgb4Y3viKQefNHbr/dPX8aAOI0bTrnU7xIbaNnJPIAr3iz8M3Phnw1DfNF5JjZZN7dCvt/KvaPht8HtL8PQI1wkTOx54wWH416JrvhzSNX0htOvrWI2mzCqvAQdv1oA+KPFMq6leXV/bZeO4Jk2Z5B9MVZ0nVY31R/NkKWOqQmCdHY7YzgBWx7ECus+IXwn1nw1JcXNnF/aGi5LrNCSzRj3A6GvKXtLi2lPlb2QMWCSNk80AXbmCSw1Qee+1DndzwT2P0qlq+shh9nWQys+VLdh+NZ+qX811apbvCFSNs7s/MfUGqgCyAseSRyew/CgCAx/Opk3Fc8c8j3pwG1SE3YPY9s1KS6ANk/KMHPT8aSJyGO4bhg5x29xQBd0+9lsrj90dq9DuOSB3rb1fWn1SSCORkEUagggYyfWubYKZGaEBhjIycmrA6K8QDBeCp60AOkEgulICq2c8Z6VuwWwBWXJORkZ/hPp6VB4fiaa+MjKSsS/dz+ldDPtRoVKjAyTzj86AH38bf2HbDO1WDMNwwevauJ1OG6tdWstT0yZY57VllR9oOyRW3A4IIPOK7nXJSml2kC/dCn7x55PasTyPMtyBnYvQdDmgDXT42/FR4w/wDwlKBScc2Ft/8AGq8/0aOTSxOzlCzAEY6r+FWxC1u0jMRvYE5Hp6GoZnVYBLGP3j+o4/OgCvO8xbeGLH0ByBUbmVQwLHaec9QKemHYMCNxHHHAx7UAK8ZOeAc4J75oARLieEJGWJVvxxW//b1m1hFbhoozgJLG2cOM5H0Nc2u3LKBsZjzkdK0fBPjPUPAniW61bSILSS+aB4I2uI96xFip3gZ+8McfXv0oA7S/13RtI8EWuk6bK0Oo3U/m3rzZyIV+4gyORnLH3A9Kr6Vci7tfNWXzVLEB8DmvV/FmvX3iH9l681b4oW9r/a1zOP7HfyRHK4JQo4A6E4kJxjKAdc8+L+Cv+Rfh/wB5v5mvNzSK9kpW1ufbcC1qix8qSk+VxbtfS+mtu5Z8Q3FxbWDSWp+cAkgqGBHvXmUrCRy+1V3c4XgV7dpVut69zZsfmngZB8u7uv5V5f4n8N3OiapLbSHeinJfGOKvLopUE0tX/mcnGdapPM505SbjG1l0V4q9vU54880vU57n0pflBOQfam5z/hXefKAxzjn/AOtSdqcmOd2ce1A75w340ABPHfFISSOfwoHXgU9TgZIzj16UAMGaDyeKQ89BSnjjFACgDvmikHAooAkTIDKThfQ+tR44yD7VKuVV8MeR06VF1oAUsx4Pr2pOcEc0A4pS5I60AIOKcS2zBBx6030pxUjGeAfWgDp/ANib7W40iK+YcYz25r6y8JaQNC0P7Zdxqzqp4C859M96+SPAeoJp3iG0mnYeVvwecV9leENbbUtOihtrcTW8SAzb/m4PQZoAwrD4napp0jfa7E3NvnqF5UH8P1r0HRPFelanpAS2MdooBxFK2Nmec89eTVYJpluDLfQwW+RlpHXoP/1Vh6t8QvA1gBDNcxyN9whIgSB6/h0oA7KfxTpGm2AjW6jnwNpRMOWOOT9K8B+JJ0TW76S+03SprOcNyx4V/Qgeh9a9N0vxl8Or+QxWtzaRzc48yLbu/PFcV8Q9d0hreYaTdRvDj5Vjxxg+vagD5u15wNSkSNcENx2IFUgwEoUrtx1weTVnWrwzajM4BdckjIwVrPRgCTuPzDGM5C0AWHd40kBjJHRueRTdyhSS2OMnPGf8ajiVzJ1cuMEYGCf8asC1uAhkaMseSoI4/wD10AMhnBZpIc7scnFXUbdlsBO5Pp7VUVhsVyhVARnjip3Ktg8YB3f5xQBv+FLgJetvcbWBUf7P+Nb/AJT3Dt8uW3cYOM4PFcnpalgE25ZhlSBz+Fd9pMBZEAQBj97J/X3oAr+JIpNlrsG+QQgt6g/5FYiTKkbbiMIclCcfrXa67as+x+CdoUDHauL1qJoMoPm4yRt4NAHO3ZjmbK7ldmzyO2emarXMLNEwVCGLZznpU85BJwNhXjBGQQfWmNsEBXb/ALoIzk9sUAU2zHwCWyBgA9B7mlgBV2Y54+9x+dSSpIHRwgYN1HeoBu8xSEYAZ6HPFAFoKksYODwcrjuK1vhbq3hfRPHL6l460i81TT4Y2aG2tolf9/uXaXVmUFQN/GeuODWEAsZBQFS69OxP9K1tD0557tHdc4bI3mgD1b4q+OfAPxCtr29n0fx3NqiWskeniRI1tbeQqdp2rIcLu2ljgkgd8CsDwJ4G1LWfCujrodnqUl5ceYboyRlIoSJWC7WzyCoBOe9ez/CTSLiS0kQSbNh+VQOG47n0r2K3E2nQpEEhL4ClhkAn0pNJ6MunUnTfNBtPyPNfA/wmTw9ZGXUDFqN3KmDgtiPuRnPPOKyfF/wqtfEMrM15a2t7gjy5sqT6ADvXtEtxmVJImIJ4cKc9P0rnNXt7e+ikS4VjIj8DaMqT0INCSSshTnKo+abu/M+G/iH4Fv8Awnq01rPHIUXuUwMdeK4tgoBA654yMHFfZPxGCap4cutN1dRNc2fEV1jBdD05/pXx/qsSwX8kYJKqTj2pklZomUj0JxzTQAOv0oYluSc9uaTIP+NAAQVODTiS7HHfoBTO39aUHHrntQAMMHoRSH6044xzyCPWg9cYwaABcDPP6UUg6dKKAHk8Yx06ZqPuO9WNodSwI75PX8KgBz1PagBMZzTuue/vQBwCDz6UEFeo5NACADac9e1Ko3MAeKUcZXHJ4wRWhpSwS3qJKjMMAD1zQAi2flws2c5xyO1e3/A/x5JpcVxFcj5NwEu4/wAIXGa4ZvD8d3aFrZiN2AMEYBArBieXR7h9oZYcEOc5oA928Xa7FrVzHIl4ptUJLhX4fPt6V51MbYzTQ6bbm4cD55HHC0eFtQgvLBbSODzppidrjt+B7mu+8U6Jb+GvD+i2eno0utXaG5nKH7m7hBnuep9qAPJ9Uhjt2Af5pyOEFZN5pz2P+tdvtDgHyQ3KqR3967+aC18MWkk988d7q8h3JErblj4zlvz/AEqt4V8MyXy3fiLVgfsNr+8lmkON7H7iDPXJoA88mRrWby7pid4GflyRkVNc2PkpHKQJoZBww5zWtb28viHX0hiQBSSSBxk/xVBE82lXUlvJiS13bTE38PPOM0AXrCzXaJVO4sMFe31/OtKK0McfkquQ3zrjqvrSaHc6bcN5fn3McfD7SOSOh5r17w3P4VmSJtWukto5Y8Ioj3FAONpYjhjQBj+FfCFjrPwa1GBlt4tUju2vocAGRocBSPp3ryfVNEEDyeZkBSNxx0HvX0Pp76TeapdW+mW88VpgRIz4JI7kkYyMV5/4w0KOx1WWKGR5AHK5xtzz60AeeaI8bs0SFgVOAx4JB9K9N0q14tkVcA45H8Vefm3eDV40VGUb85HU17hpOjuslosYYqADIhX/ADxzQBieMbYqqRooO1QCRxzivPNYiJUsWJwMBs9K9w8a6Obi8UxwjySoDlxgHgAYNeQ/EYw6WPskKuzyLt4GBgeg68UAee3fltcGEbXdPmzj73tV7wl4bv8AxNrVtplhAzSTN93+4ByST6VQs45ZbtVSNg4APJ4Ir3/4NSaf4atX1nVpUiyDFs5LMTwenPSgDkPib8PdO8M2miWtpLLLPMrNcTEffwQOPQVyEmkxxldm0KVC7Mc8c817h4oms/GBi+yKz20DH940ZVoxn5uvauB1PwtcwTF4bq2mViAWU/cHbnpnFAHEx6XbmB52QBI9qhV5JPet7QhM2tQ21paecsm0FRz1POB9K1dJ8MXusXS2kEix28YLSXD/ACooHuavav4i0DwVYTxeHbyK/wDEd6rRrcKN8duvcDjlsUAejHxPp3w8WN9TDPOwCxQR8BwPftS2Xxsi1CCbytNuGuC+YombKkZ9fpxXjc9tLqvwznn1KdpbmK7yrHkspXJH4Gs3wFdzWt/aTMshhhOWVeMjOMj04oA9gPxR1m8vFkjt4YY5Pk8pFOB/ia9D8PaxqV3Yy/aYVidcgN6g964BfBjSPBrVrueyuwVCqcmJj7fTvXSNqcOjQRWTzgSxLgE8lvQUAcx8WdV/0Vw0hJZMZA2g49a+SdSkD3k/yhQTwOvevbPi14gNzJL5k7bZMhFPX/8AVXiF598EhQ3fHf60AV+3vRjB5/D3pcno3I9qGwSefQDPpQAhGPx6UhpTwBxij0oATNLzyacoGMsSKfhRHlSC4/zxQA1FyucgUUqrwd0m056UUAORwokVgQetRLznoKfL/rGHXn8aesLA4cFSeQT60AQt3IH405w2Ofu9elSM4RQm0EL1561H8xzhvlzQAnDKoAwemakhlMEhZSd44BoBXy15IPTmoyi54btmgDo7PXZGj2I209AvSn3OrI7NC6AuxLFsZI+tc3GWDhkwBn1zirUZa2mLSR53deOMe1AHQeE9et9C1lLkpvhzlR3U16LN4in8WmSSGaO2tyS+3IJzgA4J5HToK8store+izCQJTkYK8fjTLS8m0m5/dllCHDA8hfcUAeoQeEL2+v4beAq11cOOT91U/2vTvUvxB1tBpMHh7S1RNM05izYcsZpT94k+noKi8MeL73TNC1CSB0nvbweQJccojdT7HFc7eac1srI6yeS2Nz+/pz9e1AGt4GC6RBfantRmS1cR7mwVdxj+vSuVSJ9Xu5RIyN5W52PQ8c10uspaWNoLG2aR2DIGbdkA4y30rO0yBEbUHjl2SnPDDOfx7UAc7o8/wBmm3sQq7ipZgeOa7rTV+2wzM5G+MBNvZh/e+tc1pNlLO81owUpIrEMB3HIqzocksUskrSgADaSMHIoA9L8DXFws8UjSERIdpD5zxXbeJLSO98q7iVcOnzD7xPGM+2a87064jea6trV9rywCWNyeFfFd74N1yx1TRDb3SSLqVqcOMHDH1BHrQB55dRR/wBo26NkiJgwXHTnPPr9K+gNChW7sftDRv8AIAobp27evFeb3Wnqmqm6tIXcqwIGMgkjoT9a968KpbLoERWMIGG07hznHOfSgDkNUtYrt4jI3O3q+SfwHTtXh3xWg87X7fz8RsiFjgcnJ4x+tfRXiVUj02WaEnfD8xBTHY9PavnTUZJNa1lhONkqKQBtyXJPSgDmPD+kXmt31vYaRG7h22ecwwFUnmvo2TwtZeENNsVQJJdQptknnAK8jqF96yfhXoMwkEkVsgQfMSeNh9z6+1dV42hFpZyTajIWlVSUdskt9B0oA43xJ4n0u1td+owqCV4gjOwvx/Fjt7V494n+IH2mJbfTrWKGNSDGAuc+n4+9ZHjTUGfUvI853VyQTt5Un/Cua02FtQ123to8PErhW5wRjqT70AdL4p1LUZ/DkcVzPOGuG8zyEG0Yx1OOtYWrad9j0jRJlZlkkLMzKOc5rW1eWS+1VjKv7pH+Ug8bc8CrGs2txL4WiR0CvbzZTC5ABYYH8+aAOt+HBj1Dw3r1pJIvmW8JuE3nncOB9PSp9N8MGK8aJ18uR0R25wCGAOPbnvXFaTqMVlPdi6nt4vtUIjcDrgMOc17Pcxx6jcxXNgS0TWsW1wuRwo980AdT4B8TR6bpl9o00a74wXgJHBPQg/pXk3xK11YBKVmVYwT8x4yc8gGutvYrLRrCW/1q9gsgrCQK0nzvjqAPU18+/E7xLH4q1w/2ZCEsomJQ46UAYWvX8+r6h5kKyZYbdzen07Cs66svsow3YcnrW1p+nLHYzSSufPwOeoIHY1h3txvYqCWIyOBQBRZvvKMbSc00I5xgVditH+Y4yx6EdOneoxFuf5WAUkBgD0oAqgZPHWnxngqTwevGeKldDE8hRu/6VEpOeB8xPBHHNADVYLkYzn9Kd0AwTg0i9MEHPQfWl3kAIR8o6jNACA+5/OikI9Rj6UUASsAZzuZj6nFTNKS65Y4YEcD9arhz5gOAD3xxmnP8zZUnI9TzQAkpDMzJyDweKaHdSR0PIPvSYY8ZPJ49zSFSASc5HUUAGQTnj6VKrYbgDcDwCKhNKoJBIxxQBJGFyOMvnjFSNKGCiTJdBhRjA/OoASrnpkUFnYKOTjpxQBftNRlswGi2lcbSjDPFWm1Symjf7Vbzs78nY4Az69KxecdfrTmAypB4HU46UAdT4X8Yy6BIwitop4Cc4m+Y11//AAnthqF0ZJ7OKNHK7tvXPtn+deTSACTCNvHrjGabg5G3PPSgD0iS6hurya5tnVGdmyr9x3HHpU+mToy3aSCEyld4yPvAdQPevOoJJgrKCQVO4nvVi3v7lJVdXwyA5BPUGgD0qw0y5dk1DTG8wwf66NTxGe2frVGC0EepXEb7ooZhmMbOM1leEvHt14b1COf7NHPGQFmgc/LKgPIPv6elfQtv4R0nxfotl4h8LlRbTKHMDD5oH6lDnr7UAeaeCbCZtbC3zSoGLwjcvVscV614U0Nbe+8p2jkbBBITAGe2e9XLDwlMLx7tvLfGHEW3AyOp+oruvDfh/bH9tlABkO4jOOM+lAGDPYjTy5uBvUny2jAwq+/HNdJ4S1mEwS2zxYBPmIDJ17EZ/AVuanYRtE6pEjAjeS4zhv8AGuTsoPsN+BLGDkldq8ZXP6fWgCr4x1N7tGhicxKgJmCHvjgH14rhJ/DzSMTAzR3RG6FtmSe9dVqGnvcavJcqzRFjgKDwy+/YntXY6PpULTebDsZBtBGM4PtQBJ4Ks1svClsyqIJXGZmwd2739TXPfE+O5fQJZfnUqAoduiAc/nXZSXq28K2zKqlR0x79aoaxHZazp9xbhSVI2kBzwc4xigD4l1+zuIb17y53EFyRg8sfepvBrQWC32o3EJLBCiH+9I3A59hmvavGXw1nnZbRYB5asSjK2WyTwCPWsnVfA+l+EtItLjxPcm1tgwcwucl26hQO5NAHPWmno1jGZYdpmIklcc+Wg/xqn4pktrbR3ks2clmAjhznkHJJrA8QeO0uZpE0hWtoWIVUDctjpuHp7Vyd/wCKZ50aOV1yflJA5+ox0oAetjcanqQnmk2O/ROPyxXu/wAOvPgWC2MgEqRgFGGdwAr5tTU5Y5jKkju45y54B+lb7/EPVjbwpEY4poxgTIMN+NAHsvxmv7fVbJIpYsmEFSSDx/8AWr50hVTfFBLsQN1Axx6Vrat4z17VAPt16ZRjb90AmsqPUFjQqLWEk4O45zmgD0S+FhDpLPBcAzCPcyg9vx715/FdLJcHbGAhwpP/ANeo3v5Zw29QwAwBzxUDMnzgRrGehXJNAGjM4Uh43+Xb3PT/AOvVW2IM4YPwTgenNVDK3mkqAAf4ccY+lKsx4HygZzkDGDQBr3joYgrrjIIYgYJP+FZMY8t8sAUB79DS/apAgXcWUHPzc81EXODx1/GgCe4kJOxlx3GRzVf1AwCead5rHPJJxgEnoKZ1GaAHqARyQvtjNFCykDhV/KigBZVIOeowDk0YLrkDoM59KmlTfbB+pBwagH3eCeOvNACKwQjjOPXmkBxmnvGFjDbs56gUwjacHBzQAhPp07UoBwBt71M8QERLZUqcdcg1Gy7D17AigB7BBkjggcA+tIpdHBO4A8ZFCMMgsD19eaJJDIqoXJVTxmgAkLZZiqkHqR0ot42l3LGpY4yQBSqELOhJXPQDpQQFB8o9Opzg0ANliaI4dGUHpnrTUJAwCAeuacHOd+7JPBDc1ZtFs5mVbndDnqy80AJvBkQKq4HBzz7UNlGOwglBtbHUVv3egW02li+0mUoNwjKSNkt7+1c7NDLZ3BjnGJB1x3/xoAa+1kyAB656E/Wvc/2ZPGc+g662kXcu7TdRAVQ3IV/b0rwtDvVkGck5/Cus8H2bQRXsssgiaOPzY+edw5BoA/QAPFH5v2eKEwgAb/6H1rNe/c3RhjIxIc/Lxg+lePfCjx8+teGIYPMP2qI7Zd7HpnjivQrPUVA3jeZdwwQ3UigDqri5mWMRoHUhsFzyc981l3e6OV1C4ZRgn29fpUh1OExg3DCOfuxbPT+vSqUtw12zgMfMPBZe59qAE8+SKTJgViGxkgbWBFaWnStbsMB1AIJVjxn2NZGnSmRckMZQ+HbHyqo61oeZ9lnwCDG4ycnOz3oAn1ud5EaQIQX9DkZ9PrVXR0lj2zjLMfvZHfg9O1WLPE8zxTrjacg96h8aa1Z+FNEnu52AMabtzNnHHXHegDh/jD8VbPwTZMsNsJ9XclYoz93d/eY+g618e+KvFWt+KdSe/wBd1Ce6nY8bmwqeyjoBVr4geIL3xJr82o3xk2yMWiR/4Vz/AFrnGK4AVs+vGKAG7yXHJyOhB70MhA3H1wc+tCtz8owSMUAsM4wc0AC7twI4NOGRIQevQ44zTgoKsCcAcnimKo3nALj8qAGknBx0zSklcr6jBpI1LvtXGT6mpVhXd++kCj1HNADELBWKtgd/ekYrjGDkdDQyqOEfd+GKUApgsuQelADG9uhoXGeameBsBjgHuPSiJ0RtsiA4OM+lAEcgwSACB700dOtXmMdypCDDKvG6qQUkEAj6ZoAbmilFKo3EDIHqT2oARTxRU+1V4U5HUEnFFAArOPu4C+/FNTBk6hVPekXLAjGT1xVi3RJLGffIFZOVBPWgBhGW2PlgeoHb6VXkUoxXtU29SgLrllGDzUkXllCjLuByQehHvQA2JnSIqeh+YA4xTJEGNyqdueRjofrTE4IbjIPQ961CIbuylMaiFwcgKeD+FAGcWCuDuypA6fypVXJygXDdMnp7U0RfMwyMjpjnNKuVBPVc4+hoAQg9doPc47U2Jh5ysVyAckCpIfuuecnjFJEr79salnBxwKAH3aRiXdCQQRux6VDGV3ZkU47kVfmSCNlbJaQKPlB71RuGZn+ZQvsKANqLxFdw2r2kSQCFhtclOSPQmobrUUutISGe1QSxn93KpIwvofWs4jCjcRt9BUnyqmFZQnfHNAEVtnzApJySB7iu7s7dpbSO3t2AZj+9x1PoPrXCGIoch8sO4rodN1W0tdKuFXf9oY/KpPf+9mgDd8L6xeeF/Ei3NvteykYB1U19MeGtRiv4YNTt/L2soJhzyp718Zf2hOsiyklmVs9MAmvRvAHxCOn3arczuq/3SBj3oA+k9ZufLEbIGdHySqfw/U1LYSMYEnflGyUKjBHv9KxtE8X6Rq9gfte3AHAUgEnOc1fnvLa4sRHDIsiHlCpAwPYd6ANO3vgJWSAqNo4UNw1WNNuPMhaeUpKobIROo/3q5v7XBEyNIyEoAFZOoI9aw9f8b6dYRPJZMhkAyfn49xj2oA9L8RaxZW8BupZlhEPUBv3g4z07ivnvxb4iuviBrK2dzIf7Hgm/eAH5pD2H0rgPGvj671ub5ZGbORt3ZG3NczpWvXdjN5rqJoemzOCPofWgDoviP4dtbCR5LKVnC4wqvvAFcDDC8rBY0ZyewGa29X8QzXm4QxCGMnPXJ/GsaGeeK4E0bskoO4MDjHvQBsnREtoVlv5xE7Nt8oDDVDdWttIqi1AEY5yx5/8Ar1mtM85Zp5GZhk7mOetIgYxF1OQOCM9KALltPbpI0dwodMnJB61BI9oFJjWXzM+vAHaq5IMQCqoI6nuaWOMOvUAjnJOB/wDroAd5O4Fg4wBnn0pgKA85b9OP8aljjLINpVVzyD1p7JtDKGAPdcZ/WgB0DrndEqhl5+7n8KRnVX+YHcfmAAqJFCtkAcdc9Kkf7w37XUcLt7UAMWQlyPmdjx+FSWcKXTtG3ySBSQR/ER2pkRSBwzhmYHgdPzq5Ne2mXe0tWjlYbfvZC8cke9AGc0jruQHp3xzTMlsZY9O9BBJz1pDkjHpQAAZXpUgbbFgdSeRRGxQFWBAPtTZCCxKjA7CgA3H1z9aKTBPPWigBVyDwehpSpDbgQc/lSBeRz3Ip0jbgoHAHFACIdr7sZH0pxbHUL0xioiO2akC/Ic84Ax+NACOArDvxyKljmETgqpGfvVEclizHJFAPzZ7E9O1AD3ceYHT5Vbr3xSkoMbFJIP4GnNGhLYXA7DPSoBw/BwfagC5FbpcRO6TKrgFmU8HHpUUOyKXGSwYYyOO1NhmkVSqsACeTjmnuirtcgtu5wTQBCfkHGQ3Yj1pQvOCCQB6YNXyYpZYxJCCTgE5xVe5AN4yAYRTwB6UAQFGTODnpnjpSEYU9Ce4x0qxIQ4CqoQdeO9VpE2sQTk460AO+ZWPBUgZOR+VRnI5HA9jRkk9Tz1pVAzyOO49aAFWVlPUmkLMr5XAPXjtTpVXzAFGFPOKu2extPuS0amRBkN7elAEtlr17abQsjlQOAGIret/G93DDjzZSQAFBbkCuOQkL2/GkI3KWJ5oA6q98b6lMTskkTIx949PWueu9Surv/XTO341X4CHA59TTVTd3oAWNwpzg7gOCD3p7SsU465yT/WolALAe9PePbIUz074oAQyOepJod8gDsOlAG4gdBQq5JHtQA0sTjJzU8Wx+CpHPRT1qFlwakyfK557UASiAyEiNAD0Iz0+tNhmMZdDHG4IwQwz0rS8OQrc3LLIAQibh+dN8RW0UGsTRxqFTaHIHrigClG+9HJKjPGAPypgO5TmQgDjkVCCyZwacrjksuST60ASK5KhcDZQJN2R91uoBPAqNicKD05poXcWPoKAAksxOBn0o3ADjOPSnI5jTjHrSMAQTjGOmKAGgc7V5zUkaEllHPHpSxRBgDnHI6UjZ8xlBxjjjvigBsjsRg9BxTBknA70AU+MtGA6Ng5xQA5GaNcc880U0AnnNFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Short TI Inversion Recovery (STIR) coronal oblique MR image, showing focal dysplasia in the left parahippocampal gyrus (arrow 1) and occipitotemporal gyrus (arrow 2). Cortical thickening, increased signal in the subcortical white matter, and blurring of the gray-white margin are appreciable in these two regions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15027=[""].join("\n");
var outline_f14_43_15027=null;
var title_f14_43_15028="Hydroquinone: Patient drug information";
var content_f14_43_15028=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydroquinone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/59/36788?source=see_link\">",
"     see \"Hydroquinone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aclaro PD&reg;;",
"     </li>",
"     <li>",
"      Aclaro&reg;;",
"     </li>",
"     <li>",
"      Alphaquin HP&reg;;",
"     </li>",
"     <li>",
"      Eldopaque Forte&reg;;",
"     </li>",
"     <li>",
"      Eldopaque&reg; [OTC];",
"     </li>",
"     <li>",
"      Eldoquin Forte&reg;;",
"     </li>",
"     <li>",
"      Eldoquin&reg; [OTC];",
"     </li>",
"     <li>",
"      EpiQuin&reg; Micro;",
"     </li>",
"     <li>",
"      Esoterica&reg; Daytime [OTC];",
"     </li>",
"     <li>",
"      Esoterica&reg; Nighttime [OTC];",
"     </li>",
"     <li>",
"      Lustra-AF&reg;;",
"     </li>",
"     <li>",
"      Lustra-Ultra&trade;;",
"     </li>",
"     <li>",
"      Lustra&reg;;",
"     </li>",
"     <li>",
"      Melpaque HP&reg;;",
"     </li>",
"     <li>",
"      Melquin HP&reg;;",
"     </li>",
"     <li>",
"      Melquin-3&reg;;",
"     </li>",
"     <li>",
"      NeoStrata&reg; HQ Skin Lightening [OTC];",
"     </li>",
"     <li>",
"      Nuquin HP&reg;;",
"     </li>",
"     <li>",
"      Palmer's&reg; Skin Success&reg; Eventone&reg; Fade Cream [OTC];",
"     </li>",
"     <li>",
"      Palmer's&reg; Skin Success&reg; Eventone&reg; Fade Milk [OTC];",
"     </li>",
"     <li>",
"      Palmer's&reg; Skin Success&reg; Eventone&reg; Ultra Fade Serum [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F180681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eldopaque&reg;;",
"     </li>",
"     <li>",
"      Eldoquin&reg;;",
"     </li>",
"     <li>",
"      Glyquin&reg; XM;",
"     </li>",
"     <li>",
"      Lustra&reg;;",
"     </li>",
"     <li>",
"      NeoStrata&reg; HQ;",
"     </li>",
"     <li>",
"      Solaquin Forte&reg;;",
"     </li>",
"     <li>",
"      Solaquin&reg;;",
"     </li>",
"     <li>",
"      Ultraquin&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the color of freckles on the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702270",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydroquinone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are sunburned.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After stopping this drug, some of the color change may come back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Practice good skin care and avoid the sun.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11761 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15028=[""].join("\n");
var outline_f14_43_15028=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180680\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180681\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025632\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025631\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025636\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025637\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025639\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025634\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025635\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025640\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025641\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/59/36788?source=related_link\">",
"      Hydroquinone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_43_15029="Management of malignant gliomas in elderly patients";
var content_f14_43_15029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of malignant gliomas in elderly patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/43/15029/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/43/15029/contributors\">",
"     Tracy Batchelor, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/43/15029/contributors\">",
"     Helen A Shih, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/43/15029/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/43/15029/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/43/15029/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/43/15029/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/43/15029/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/43/15029/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H465177\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older patients constitute approximately one-half of patients with malignant gliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Among clinical factors affecting prognosis, older age, and poor performance status have consistently been shown to be associated with shorter survival [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The poorer prognosis and high frequency of comorbidity have led to controversy about the optimal management of malignant gliomas in the older population. The available evidence and approach to these patients will be reviewed here. The general approach to surgery, radiation therapy, and adjuvant chemotherapy for patients with malignant gliomas is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"     \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link&amp;anchor=H5#H5\">",
"     \"Adjuvant chemotherapy for malignant gliomas\", section on 'Temozolomide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=see_link\">",
"     \"Adjuvant radiation therapy for malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H465193\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involved field radiation therapy (RT) of malignant gliomas in the elderly is effective in providing palliation and prolonging survival. However, the optimal dose and schedule remain uncertain, and many elderly patients are not able to tolerate the prolonged courses of RT used in younger patients. The impact of radiation on malignant gliomas in the elderly has been studied in two randomized trials in which RT was given without chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=see_link&amp;anchor=H3#H3\">",
"     \"Adjuvant radiation therapy for malignant gliomas\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The survival benefit of RT in the elderly was demonstrated in a trial in which 85 patients, age &ge;70 with either grade III or IV gliomas, were randomly assigned to best supportive care, with or without involved field RT (50 Gy in 1.8 Gy fractions) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/4\">",
"       4",
"      </a>",
"      ]. Progression-free and overall survival rates were significantly increased with RT compared to best supportive care alone (15 versus 5 weeks and 29 versus 17 weeks, respectively). There was no impairment of quality of life or cognitive function associated with RT.",
"     </li>",
"     <li>",
"      Lower doses of radiation and shorter courses of treatment may offer an advantage because of decreased toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. This approach was illustrated by a trial in which 100 patients with GBM aged &ge;60 years were randomly assigned to treatment with 40 Gy in 15 fractions over three weeks or 60 Gy in 30 fractions over six weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/5\">",
"       5",
"      </a>",
"      ]. The shortened schedule of RT produced a comparable survival (5.6 versus 5.1 months with the six-week RT course), and fewer patients required an increase in posttreatment corticosteroid dosage (23 versus 49 percent). These shorter regimens may be particularly appropriate for elderly patients with malignant gliomas, especially those with a poor functional status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H465201\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    , an oral alkylating agent, is the preferred agent for adjuvant chemotherapy in patients with malignant gliomas, based primarily upon the results of a phase III trial conducted by the EORTC and NCIC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In that trial, the combination of temozolomide plus radiation therapy significantly prolonged survival compared to radiation therapy alone. The results of that trial are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link&amp;anchor=H5#H5\">",
"     \"Adjuvant chemotherapy for malignant gliomas\", section on 'Temozolomide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of concerns about the toxicity associated with radiation therapy in older patients, chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    has been studied as an alternative to radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Older, small studies suggested that temozolomide has activity, but have not established the optimal way to integrate temozolomide into the routine management of older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/9,10,12,13\">",
"     9,10,12,13",
"    </a>",
"    ]. The use of chemotherapy in this population may also be subject to increased toxicity compared to a younger group with less comorbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link&amp;anchor=H15#H15\">",
"     \"Systemic chemotherapy for cancer in elderly persons\", section on 'Comorbidity and functional status'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H465209\">",
"    <span class=\"h1\">",
"     CONTEMPORARY RANDOMIZED TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two large, randomized trials conducted exclusively in older patients provide conflicting data about the optimal approach to this population. In both the Methusalem (NOA-08) trial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/1\">",
"     1",
"    </a>",
"    ] and the Nordic Clinical Brain Tumor Study Group trial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/14\">",
"     14",
"    </a>",
"    ], a strategy of initial chemotherapy as monotherapy was compared to initial RT alone. Additional insight is also available from a subset analysis of older patients in the EORTC-NCIC trial, in which all patients received RT with or without adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, both of these randomized trials differed significantly from the combined chemotherapy plus RT schedule that has been shown to improve survival in patients with malignant glioblastoma; thus we continue to recommend the standard chemotherapy plus RT regimen in this age group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466074\">",
"    <span class=\"h2\">",
"     Methusalem (NOA-08) trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the randomized Methusalem trial (NOA-08), 373 patients aged 65 years and older were treated with either single modality treatment using radiation therapy or chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/1\">",
"     1",
"    </a>",
"    ]. Chemotherapy consisted of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    for 7 days, repeated every 14 days), while RT was to be given in 30 fractions of 1.8 to 2.0 Gy given over six to seven weeks (total dose 60 Gy). The schedule of temozolomide in this protocol differed significantly from the daily schedule now widely used in the treatment of glioblastoma.",
"   </p>",
"   <p>",
"    Upon progression, patients received salvage therapy if possible, which generally consisted of RT for those assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    and chemotherapy (temozolomide) for those originally managed with RT. Approximately 90 percent of patients had glioblastoma and the remainder had anaplastic astrocytoma.",
"   </p>",
"   <p>",
"    Key results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall survival was similar in the two treatment arms (median 8.6 versus 9.6 months, HR 1.09, 95% CI 0.84-1.42), which met the prespecified definition of noninferiority.",
"     </li>",
"     <li>",
"      MGMT promoter methylation status was tested in 56 percent of the study subjects. In this subset analysis, 35 percent of patients were positive for promoter methylation. In a subset analysis based upon these results, the presence of MGMT promoter methylation was associated with significantly longer overall survival compared with those in whom this marker was absent (11.9 versus 8.2 months, HR 0.62, 95% CI 0.42-0.91).",
"     </li>",
"     <li>",
"      Preliminary analysis of adverse events on the two treatment arms presented at the 2012 American Society of Clinical Oncology (ASCO) meeting found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      was associated with significantly more grade 2 or higher hematologic toxicity, liver enzyme abnormalities, and thromboembolic events [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/15\">",
"       15",
"      </a>",
"      ]. The impact on quality of life and neurocognitive function were not assessed.",
"     </li>",
"     <li>",
"      Patients whose tumors had MGMT promoter methylation appeared to respond preferentially to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      (median event-free survival 8.4 versus 4.6 months). In contrast, those patients whose tumors did not contain MGMT promoter methylation did worse with temozolomide rather than initial radiation therapy (median event-free survival 3.3 versus 4.6 months). Additional data from this and other trials will be required to determine whether MGMT promoter methylation status should be used as a criterion to alter therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466081\">",
"    <span class=\"h2\">",
"     Nordic Clinical Brain Tumor Study Group Trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Nordic Clinical Brain Tumor Study Group trial enrolled 342 patients aged 60 years or older with a diagnosis of glioblastoma; the median age was 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/16\">",
"     16",
"    </a>",
"    ]. In this trial, 291 patients were randomly assigned to one of three arms: two RT schedules (standard [60 Gy in 30 fractions] or hypofractionated [34 Gy in 10 fractions]) or chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for five days with cycles repeated every 28 days). An additional 51 patients were randomly assigned to either temozolomide or hypofractionated RT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the three arm randomization, overall survival was significantly longer with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      compared with standard RT (median 8.3 versus 6.0 months, HR 0.70, 95% CI 0.52-0.93).",
"     </li>",
"     <li>",
"      For all patients given either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      or hypofractionated RT, the difference in overall survival was not significant (8.4 versus 7.5 months, HR 0.82, 95% CI 0.63-1.06).",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      was associated with significantly longer overall survival in those patients whose tumor had MGMT promoter methylation compared with those without MGMT promoter methylation (9.7 versus 6.8 months, HR 0.56, 95% CI 0.34-0.93). MGMT promoter methylation status did not have a significant effect on the response to RT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466042\">",
"    <span class=\"h2\">",
"     EORTC-NCIC trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the EORTC-NCIC was limited to patients 18 to 70 years of age, the five-year analysis of results included a breakdown of outcomes based upon age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/8\">",
"     8",
"    </a>",
"    ]. Within that study, 170 of the 573 patients (30 percent) were aged 61 to 70 years.",
"   </p>",
"   <p>",
"    For this older subset of patients, there was no improvement in median survival using the combined modality approach compared to radiation therapy alone (median 10.9 versus 11.8 months). However, there was a statistically significant prolongation in overall survival with adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    compared to radiation therapy alone due to an increased number of relatively long-term survivors (22 versus 6 percent at two years and 7 versus 0 percent at five years, respectively, hazard ratio [HR] 0.7, 95% CI 0.5-0.97).",
"   </p>",
"   <p>",
"    The results of the EORTC-NCIC trial highlight the potential impact of treatment on a relatively small subset of patients who may have relatively prolonged survival following aggressive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H701992875\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no formal clinical trials that define the optimal frequency for follow-up after treatment. Consistent with guidelines from the National Comprehensive Cancer Network (NCCN), a repeat MRI should be obtained in patients with a malignant glioma about four weeks after completion of radiation therapy, then every two to four months for two to three years, and less frequently thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15029/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4821?source=see_link\">",
"     \"Assessment of disease status and surveillance after treatment in patients with brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H465217\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For older patients presenting with a malignant glioma, careful assessment of the patient&rsquo;s overall clinical status and comorbidities is essential. A comprehensive geriatric assessment may be useful in this setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"       \"Comprehensive geriatric assessment for patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Maximal surgical resection consistent with preservation of neurologic function is the initial step in management. Although gross total resection is preferred whenever possible, subtotal resection or stereotactic biopsy may be required depending upon the location and extent of the tumor and the overall condition of the patient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"       \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For older patients with a good performance and without serious comorbidity, we recommend combined adjuvant radiation therapy (RT) and chemotherapy following surgery or biopsy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although this approach has not been associated with an increase in median survival, a subset of patients appears to have a significantly prolonged survival following aggressive therapy. (See",
"      <a class=\"local\" href=\"#H466042\">",
"       'EORTC-NCIC trial'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link&amp;anchor=H4#H4\">",
"       \"Adjuvant chemotherapy for malignant gliomas\", section on 'Glioblastoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For older patients who are not candidates for a combined modality approach because of poor functional status or significant comorbidity, we suggest shorter courses of radiation therapy (eg, 40 Gy in 15 fractions), which are more convenient and may offer an advantage because of decreased toxicity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The role of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      chemotherapy as an alternative to RT remains uncertain. (See",
"      <a class=\"local\" href=\"#H465193\">",
"       'Radiation therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H465209\">",
"       'Contemporary randomized trials'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/1\">",
"      Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/2\">",
"      Weller M, Platten M, Roth P, Wick W. Geriatric neuro-oncology: from mythology to biology. Curr Opin Neurol 2011; 24:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/3\">",
"      Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 2003; 30:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/4\">",
"      Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007; 356:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/5\">",
"      Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004; 22:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/6\">",
"      Lutterbach J, Ostertag C. What is the appropriate radiotherapy protocol for older patients with newly diagnosed glioblastoma? J Clin Oncol 2005; 23:2869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/7\">",
"      Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/8\">",
"      Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/9\">",
"      Glantz M, Chamberlain M, Liu Q, et al. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003; 97:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/10\">",
"      Chinot OL, Barrie M, Frauger E, et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 2004; 100:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/11\">",
"      G&aacute;llego P&eacute;rez-Larraya J, Ducray F, Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011; 29:3050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/12\">",
"      Brandes AA, Franceschi E, Tosoni A, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 2009; 115:3512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/13\">",
"      Brandes AA, Vastola F, Basso U, et al. A prospective study on glioblastoma in the elderly. Cancer 2003; 97:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/14\">",
"      Malmstrom A, Gronberg BH, Stupp R. Glioblastoma (GBM) in Elderly Patients: A Randomized Phase III Trial Comparing Survival in Patients Treated with 6-week Radiotherapy (RT) versus hypofractionated RT over 2 weeks versus Temozolomide single agent Chemotherapy (TMZ) for Glioblastoma (GBM) in the Elderly. J Clin Oncol 2010; 28:949s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/15\">",
"      Wick W, et al. MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial. J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15029/abstract/16\">",
"      Malmstr&ouml;m A, Gr&oslash;nberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13:916.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN guidelines file://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15246 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.236-33BC93883C-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15029=[""].join("\n");
var outline_f14_43_15029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H465217\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H465177\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H465193\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H465201\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H465209\">",
"      CONTEMPORARY RANDOMIZED TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H466074\">",
"      Methusalem (NOA-08) trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H466081\">",
"      Nordic Clinical Brain Tumor Study Group Trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H466042\">",
"      EORTC-NCIC trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H701992875\">",
"      SURVEILLANCE AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H465217\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=related_link\">",
"      Adjuvant chemotherapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=related_link\">",
"      Adjuvant radiation therapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4821?source=related_link\">",
"      Assessment of disease status and surveillance after treatment in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=related_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_43_15030="Acanthosis nigricans - close view";
var content_f14_43_15030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acanthosis nigricans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Close view of acanthosis nigricans on the posterior neck. Hyperpigmented velvety plaques are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15030=[""].join("\n");
var outline_f14_43_15030=null;
var title_f14_43_15031="Types of hepatic resection";
var content_f14_43_15031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Types of hepatic resection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 677px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The types of hepatic resection are based on the anatomic nomenclature. \"Wedge resection\" refers to any nonanatomic liver resection exclusive of biopsy. \"Sectorectomy\" refers to any one of the following: right anterior sectorectomy, right posterior sectorectomy, left medial sectorectomy, and left lateral sectorectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15031=[""].join("\n");
var outline_f14_43_15031=null;
var title_f14_43_15032="Fetal circulation 1";
var content_f14_43_15032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Fetal circulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 629px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The degree of oxygen saturation is indicated by shading, as explained in the figure key.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15032=[""].join("\n");
var outline_f14_43_15032=null;
var title_f14_43_15033="Clinical features, diagnosis, and management of relapsing fever";
var content_f14_43_15033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"64\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, diagnosis, and management of relapsing fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/43/15033/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/43/15033/contributors\">",
"     Alan G Barbour, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/43/15033/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/43/15033/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/43/15033/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/43/15033/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/43/15033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsing fever, caused by spirochetes of the Borrelia genus, is an arthropod-borne infection that occurs in two major forms: tick-borne (TBRF) and louse-borne (LBRF) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tick-borne relapsing fever is a zoonosis and is enzootic in many countries. The two main Borrelia spp involved in North America are B. hermsii (in the mountainous West) and B. turicatae (in the Southwest and South Central region). Other tick-borne species cause relapsing fever on other continents.",
"     </li>",
"     <li>",
"      Louse-borne relapsing fever is caused by B. recurrentis. It is principally a disease seen in the developing world; it is spread from person to person by the body louse and can occur in epidemics, including large ones involving millions of people.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As the name implies, relapsing fever is characterized by recurrent episodes of fever, which accompanies spirochetemia. The disease relapses are due to antigenic variation by the spirochetes.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, treatment, and prevention of relapsing fever will be reviewed here. Borrelia miyamotoi, a Borrelia species related to the agents of relapsing fever, has been found in some of the same tick vectors and rodent reservoirs as for Lyme disease agents in North America, Europe, and Asia. Several reports have described clinical syndromes in patients with evidence of B. miyamotoi infection. B. miyamotoi infection will also be discussed below. The microbiology, pathogenesis, and epidemiology of relapsing fever are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39336?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of relapsing fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsing fever presents with the sudden onset of fever, punctuated by an intervening afebrile period, which occurs at least twice [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The temperature may be as high as 43&ordm;C and is usually above 39&ordm;C.",
"   </p>",
"   <p>",
"    Following initial infection and during relapses, a succession of Borrelia serotypes appear in the blood. Each serotype is individually defined by antigenically distinct surface proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/7\">",
"     7",
"    </a>",
"    ]. Studies in experimental mice infected with B. turicatae suggest that these variable proteins also determine differences in disease expression. For example, propensity for invasion of the central nervous system with B. turicatae infection is determined by variability in a single surface protein of the bacterium [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39336?source=see_link&amp;anchor=H7#H7\">",
"     \"Microbiology, pathogenesis, and epidemiology of relapsing fever\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Course of the fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;In LBRF, the first episode of fever is unremitting for three to six days; it is typically followed by a single milder episode. In TBRF, multiple febrile periods last from one to three days each (",
"    <a class=\"graphic graphic_figure graphicRef64476 \" href=\"UTD.htm?18/2/18478\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. In both forms, the interval between fevers ranges from 4 to 14 days.",
"   </p>",
"   <p>",
"    The first fever episode ends by crisis, consisting of rigors, a further elevation in temperature, and increases in pulse and blood pressure, lasting approximately 15 to 30 minutes. The crisis phase is followed by profuse diaphoresis, falling temperature, and hypotension, which usually persists for several hours. Mortality from untreated relapsing fever is most common during the crisis and its immediate aftermath.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms accompanying the fever can be protean and nonspecific. Headache, neck stiffness, arthralgia, myalgia, and nausea may accompany the first and subsequent episodes. The patient with relapsing fever may experience dizziness and unsteady gait. A nonproductive cough is common during LBRF and may, in combination with high fever and myalgias, suggest influenza. Acute respiratory distress syndrome may occur during TBRF [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/10\">",
"     10",
"    </a>",
"    ]. Localizing neurologic symptoms, including hemiplegia, facial palsy, myelitis, and radiculopathy, are more common in TBRF than LBRF. Delirium or apathy and occasionally stupor or coma can occur in both forms.",
"   </p>",
"   <p>",
"    Although the first episode of illness tends to be the most severe, some complications, particularly localized neurologic ones, are more common during subsequent febrile periods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epistaxis, petechiae, and ecchymoses are common during LBRF but not TBRF [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The bleeding disorder is probably the consequence of thrombocytopenia, impaired hepatic production of clotting factors,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blockage of small vessels by aggregates of spirochetes, erythrocytes, and platelets.",
"   </p>",
"   <p>",
"    Splenomegaly, which the patient can experience as abdominal or left shoulder pain, is also common in both LBRF and TBRF. The majority of patients with LBRF and about 10 percent of patients with TBRF have enlarged livers.",
"   </p>",
"   <p>",
"    Although most patients with relapsing fever have not had electrocardiograms, myocarditis appears to be common in both LBRF and TBRF. Heart involvement has been prominent in fatal cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/13\">",
"     13",
"    </a>",
"    ]. The most common evidence of myocarditis is gallops on cardiac auscultation. While patients frequently complain of polyarthralgia, enlarged, painful joints are unusual.",
"   </p>",
"   <p>",
"    Neurologic findings are more common in tick-borne than louse-borne relapsing fever and are due to direct invasion of spirochetes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/14\">",
"     14",
"    </a>",
"    ]. Meningitis or meningoencephalitis are serious consequences of this invasion, which can result in residual hemiplegia or aphasia. Unilateral or bilateral Bell's palsy or deafness from seventh or eighth cranial nerve involvement are the most common forms of cranial neuritis in TBRF; if it occurs, cranial neuritis typically presents in the second or third febrile episode, not the first. Visual impairment from unilateral or bilateral iridocyclitis or panophthalmitis may be permanent.",
"   </p>",
"   <p>",
"    In LBRF, neurologic manifestations such as altered mental state or stiff neck are thought to be secondary to the spirochetemia rather than direct invasion of organisms into the central nervous system (CNS) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/14\">",
"     14",
"    </a>",
"    ]. Subarachnoid hemorrhage has been observed, perhaps due to disseminated intravascular coagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;General laboratory studies are not specific in relapsing fever. A mild to moderate normocytic anemia is common, but frank hemolysis and hemoglobinuria do not occur. Leukocyte counts are usually in the normal range or only slightly elevated, and there can be leukopenia during the crisis. Platelet counts can fall below",
"    <span class=\"nowrap\">",
"     50,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Laboratory",
"    evidence of hepatitis can occur with elevated serum concentrations of unconjugated bilirubin and aminotransferases; the prothrombin and partial thromboplastin times may be moderately prolonged. Hypoalbuminemia can occur but is more often due to malnutrition than hepatic dysfunction.",
"   </p>",
"   <p>",
"    The electrocardiogram may reveal a prolonged QTc interval in patients with myocarditis. Some such patients have cardiomegaly and pulmonary edema on chest radiograph.",
"   </p>",
"   <p>",
"    Analysis of the cerebrospinal fluid (CSF) is indicated in cases of suspected relapsing fever when there are signs of meningitis or meningoencephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/14\">",
"     14",
"    </a>",
"    ]. The presence of a mononuclear pleocytosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mildly to moderately elevated protein levels in the CSF provides justification for intravenous antibiotic therapy in patients with tick-borne relapsing fever. Glucose concentrations in the CSF are usually not depressed. Thus, the CSF examination usually excludes bacterial and most other nonviral infectious causes of meningitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of both common and less frequent conditions can mimic relapsing fever. In addition, other illnesses may accompany the louse-borne form. The Ornithodoros ticks, which are vectors of TBRF, are not known to transmit other infections to humans. In sub-Saharan Africa, patients with fever may have both malaria and TBRF [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Under the conditions that foster epidemics of louse-borne diseases, patients can also acquire epidemic typhus, typhoid, measles, and tuberculosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39336?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of relapsing fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending on the history of travel, residential, occupational, and recreational exposures, the differential diagnosis of relapsing fever includes one or more of the following infections:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Malaria",
"     </li>",
"     <li>",
"      Ehrlichiosis and anaplasmosis",
"     </li>",
"     <li>",
"      Babesiosis",
"     </li>",
"     <li>",
"      Influenza",
"     </li>",
"     <li>",
"      Typhoid fever",
"     </li>",
"     <li>",
"      Tularemia",
"     </li>",
"     <li>",
"      Brucellosis",
"     </li>",
"     <li>",
"      Colorado tick fever",
"     </li>",
"     <li>",
"      Rickettsioses",
"     </li>",
"     <li>",
"      Dengue",
"     </li>",
"     <li>",
"      Leptospirosis",
"     </li>",
"     <li>",
"      Rat-bite fever",
"     </li>",
"     <li>",
"      Meningococcemia",
"     </li>",
"     <li>",
"      Viral hepatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, returning travelers from Africa or Central America who present with a recurrent fever on arrival or within a few days may have relapsing fever in addition to, or instead of, malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lyme disease is another infection caused by species of Borrelia, but the clinical manifestations differ in several ways. In addition, there are few geographic areas in the world where both relapsing fever and Lyme disease are endemic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsing fever should be considered in a patient with the characteristic fever pattern, especially if the recurrent fevers are accompanied by the crisis phenomenon and an epidemiologic history of exposure to body lice or soft-bodied ticks in geographic areas where LBRF or TBRF fever is endemic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Direct visualization procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thin and thick smears of blood are usually the first tests performed for suspected relapsing fever. Giemsa or Wright stains typically reveal the spirochetes in a methanol-fixed thin smear if the concentration of microorganisms is greater than",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      5",
"     </sup>",
"     /mL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef63059 \" href=\"UTD.htm?22/37/23135\">",
"     picture 1",
"    </a>",
"    ). As many as 200 oil immersion fields should be viewed before judging the smear to be negative. The optimum time to obtain blood is between the fever's onset and its peak. Once the temperature is declining or is back to the normal range in the absence of antipyretics, spirochetes usually cannot be visualized in blood. In the past, laboratory technicians carefully reviewing a routine peripheral smear for a white cell differential count often made the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/18\">",
"     18",
"    </a>",
"    ]. With current automated procedures for blood smear analysis, this would no longer occur; request for a manual examination would have to be made.",
"   </p>",
"   <p>",
"    A thick smear is a more sensitive assay detecting at least one log fewer organisms",
"    <span class=\"nowrap\">",
"     (10",
"     <sup>",
"      4",
"     </sup>",
"     /mL",
"    </span>",
"    of blood). The slide should first be treated with 0.5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    to lyse hemoglobin and then stained with Giemsa or Wright stain. The acetic acid treatment can be omitted if the smear is stained with acridine orange [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/19\">",
"     19",
"    </a>",
"    ], which binds to nucleic acids in the spirochetes, and then examined microscopically under ultraviolet light. Direct or indirect immunofluorescence is another procedure that can be used with thick or thin smears to visualize spirochetes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/20\">",
"     20",
"    </a>",
"    ]. Fluorescein-labeled polyclonal antibody to Borrelia species is commercially available and is useful for detecting relapsing fever spirochetes in the blood or in tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The slides can be fixed with methanol; acetic acid treatment is not necessary.",
"   </p>",
"   <p>",
"    A further increase in sensitivity can be achieved by centrifugation of heparinized or citrated blood followed by examination of the buffy coat and overlying plasma. As few as 10",
"    <sup>",
"     3",
"    </sup>",
"    <span class=\"nowrap\">",
"     spirochetes/mL",
"    </span>",
"    of blood can be detected. The anticoagulated blood can be centrifuged in capillary tubes, the same procedure used for a microhematocrit. Spirochetes are usually found in the same fraction as platelets. Examination for platelets in the suspension serves as a quality control on the centrifugation step as long as the patient is not severely thrombocytopenic; if platelets are not present, the centrifugation has been too rapid or long.",
"   </p>",
"   <p>",
"    Another diagnostic maneuver is the wet mount. Uncentrifuged plasma or the concentrated buffy coat is examined by phase contrast or dark field microscopy for motile spirochetes. The wet mount is prepared by merging one drop of citrated or heparinized blood with one drop of normal saline or phosphate-buffered saline under a cover slip. Areas at the interface between the saline and blood erythrocytes are examined at approximately 400X magnification. Coiling, uncoiling, and bending movements of the spirochetes as they swim among the erythrocytes can be visualized.",
"   </p>",
"   <p>",
"    All of these direct visualization methods facilitate diagnosis. A smear or wet mount properly evaluated can be diagnostic since Borrelia spp are an unlikely contaminant and an asymptomatic carrier state is not known to occur. In less experienced hands, however, stain artifacts in blood smears and incorrect interpretation of wet-mounts may produce false diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;When relapsing fever is suspected but spirochetes are not directly visualized by the above techniques, laboratory confirmation of the clinical diagnosis requires techniques that are not available in most laboratories, namely animal inoculation and in vitro cultivation.",
"   </p>",
"   <p>",
"    Inoculation of blood into weanling mice may yield a Borrelia spp from the blood or, less commonly, from CSF even between fever episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/20,23,24\">",
"     20,23,24",
"    </a>",
"    ]. Most of the agents of tick-borne relapsing fever will infect and proliferate in mice. However, Borrelia recurrentis, the agent of LBRF, infects mice only transiently, if at all.",
"   </p>",
"   <p>",
"    For suspected TBRF, blood, plasma, buffy coat, or CSF is injected intraperitoneally into the mouse; most inbred or outbred strains are suitable. Infection of the mouse is enhanced by the severe combined immunodeficiency (SCID) phenotype, or by splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/25\">",
"     25",
"    </a>",
"    ]. Blood of the inoculated mice should be examined daily for presence of the spirochetes for seven days.",
"   </p>",
"   <p>",
"    In vitro cultivation is an alternative to animal inoculation for demonstrating the organism in blood. Kelly's medium and its most commonly used derivative, Barbour-Stoenner-Kelly (BSK) medium, support the growth of most Borrelia spp [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. Supplementation of the medium with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , phosphomycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    reduces growth of contaminants. Cultures are inoculated with several drops of blood or plasma and incubated at 34 to 36&ordm;C in tightly-capped tubes for up to two weeks. Samples of the cultures are examined every day or other day by dark-field or phase-contrast microscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polymerase chain reaction (PCR) is useful for the diagnosis of relapsing fever [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. PCR can be performed on blood samples or culture medium that is growing Borrelia species, and can identify the infecting species [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Serologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most infections, serology provides indirect evidence of disease when an etiologic agent cannot be detected directly. Such is not the case for relapsing fever because specific diagnostic Borrelia antibodies have not been defined. Currently available serologic assays based upon whole cells of a relapsing fever Borrelia species, may not include the antigens to which the patient is responding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/34\">",
"     34",
"    </a>",
"    ]. Enzyme linked immunosorbent assay (ELISA) or IFA on whole cells offers the greatest diagnostic value. However, paired acute and convalescent sera must be analyzed in the same assay and must demonstrate a fourfold or greater change in titer. These assays are only available at a few reference laboratories.",
"   </p>",
"   <p>",
"    Convalescent sera from the majority of patients with relapsing fever may give cross-reactive positive reactions in a commercially available ELISA assay for antibodies to Borrelia burgdorferi [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/35\">",
"     35",
"    </a>",
"    ]. For these ELISA results to be considered supportive of the diagnosis of relapsing fever, however, the Western blot assay for Lyme disease and treponeme-specific assays for syphilis should be negative. Recombinant antigens, such as GIpQ, that are specific for relapsing fever species may provide a basis for discriminating between relapsing fever and Lyme disease by serologic assay [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], but this assay is not commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillins and tetracyclines have been the antibiotics of choice for relapsing fever for several decades. There is no evidence that Borrelia spp have acquired resistance to antibiotics. The minimum inhibitory concentrations (MICs) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    for Borrelia spp are generally &lt;0.1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/29,38\">",
"     29,38",
"    </a>",
"    ]. Relapsing fever Borrelia spp are also susceptible in vitro to cephalosporins, macrolides, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    but there is less clinical experience with these antibiotics. Borrelias are relatively resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , sulfonamides, fluoroquinolones,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , and aminoglycosides.",
"   </p>",
"   <p>",
"    The effectiveness of the antibiotic therapy of relapsing fever can be assessed by observing the clearance of spirochetes from the blood. Most patients will no longer have detectable spirochetes in the blood within eight hours of the first dose of an effective antibiotic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Louse-borne relapsing fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single dose of antibiotic is usually sufficient for the treatment of LBRF [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]; the recurrence rate after antibiotics is less than five percent. For adults, a single dose of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (500 mg), oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (200 mg), or intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12661?source=see_link\">",
"     penicillin G procaine",
"    </a>",
"    (400,000 to 800,000 units) is effective. The corresponding doses for children are oral tetracycline at 12.5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    oral doxycycline at 5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    procaine at 200,000 to 400,000 units. When the patient cannot take tetracycline by mouth, the intravenous dose is 250 or 500 mg for adults. Since tetracycline is contraindicated in pregnant and nursing women and in children less than nine years old, in those who are allergic to penicillin, an alternative is oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , 500 mg for adults and 12.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for children. Tetracycline is the preferred oral agent in those without a contraindication since it has better efficacy than erythromycin. In addition, a meta-analysis of several trials of antibiotic regimens for LBRF reported that for adults, oral or intravenous tetracycline is marginally superior to penicillin G by the criteria of time to clearance of fever and relapse rate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/43\">",
"     43",
"    </a>",
"    ]. There was no difference in mortality rates between the two antibiotics",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Tick-borne relapsing fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;TBRF is more sporadic than LBRF; consequently, the evidence about the efficacies of different treatment schedules is more anecdotal. Nevertheless, the clinical experience to date indicates that the relapse rate of TBRF is 20 percent or higher after single dose treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/6,44,45\">",
"     6,44,45",
"    </a>",
"    ], which is probably due to brain invasion by TBRF spirochetes. Protected by the blood-brain barrier, TBRF spirochetes can reinvade the blood once antibiotic levels have fallen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The preferred treatment for TBRF in adults is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (500 mg or 12.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally every six hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily), both for 10 days. When tetracyclines are contraindicated, the alternative is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (500 mg or 12.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally every six hours) for 10 days. If a beta-lactam antibiotic is given, it should be administered intravenously rather than orally, especially if central nervous system involvement is confirmed or suspected.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     Penicillin G",
"    </a>",
"    (3 million units IV every four hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV once daily or 1g IV twice daily) for 10 to 14 days for adults is effective intravenous treatment for Lyme disease. Based on animal studies, these regimens are likely to be effective for relapsing fever with neurologic involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Jarisch-Herxheimer reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jarisch-Herxheimer reactions (JHR) occur following antibiotic treatment for a number of spirochetal and bacterial infections; symptoms and signs include rigors, fever, and hypotension. Treatment of LBRF is the classic situation in which this reaction arises, occurring in approximately 80 percent of treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/46\">",
"     46",
"    </a>",
"    ]. Both penicillin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    can induce JHR [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/43\">",
"     43",
"    </a>",
"    ]. JHR can also occur following treatment of TBRF, with an incidence of 54 percent in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/35\">",
"     35",
"    </a>",
"    ]. These reactions tend to occur within two hours of antibiotic administration; thus, observation for several hours after treatment is recommended. Treatment of an otherwise undifferentiated febrile illness with antibiotics may result in an unexpected worsening of the patient&rsquo;s condition, which should raise the suspicion for relapsing fever if epidemiologic risk factors are present.",
"   </p>",
"   <p>",
"    Proinflammatory cytokines, especially tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-8, have been implicated in the pathogenesis of this process [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/46\">",
"     46",
"    </a>",
"    ]. In one study of 49 patients with proven LBRF, pretreatment with anti-TNF-alpha antibodies reduced the incidence of rigors from 90 percent in placebo recipients to 50 percent and the mean increase in temperature from 1.5&ordm;C to only 0.8&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/42\">",
"     42",
"    </a>",
"    ]. However, administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    or recombinant IL-10 did not affect the occurrence or degree of JHR [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality rates for untreated LBRF and TBRF are in the ranges of 10 to 70 percent and 4 to 10 percent, respectively. With prompt treatment with appropriate antibiotics, the death rate for LBRF is 2 to 5 percent and for TBRF is less than 2 percent. Features associated with a poor prognosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stupor or coma on admission",
"     </li>",
"     <li>",
"      Diffuse bleeding",
"     </li>",
"     <li>",
"      Myocarditis",
"     </li>",
"     <li>",
"      Poor hepatic function",
"     </li>",
"     <li>",
"      Bronchopneumonia",
"     </li>",
"     <li>",
"      Coinfection with typhus, typhoid [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/49\">",
"       49",
"      </a>",
"      ], or malaria [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mortality rate from JHR in LBRF in the absence of adequate monitoring and resuscitation measures is approximately 5 percent (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Jarisch-Herxheimer reactions'",
"    </a>",
"    above). Some patients have survived the crisis or JHR, only to die suddenly later that day or the next, perhaps from an arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsing fever during pregnancy frequently leads to abortion or stillbirth. There appears to be transplacental transmission of the infection or a newborn may be infected at birth. Pregnant women and infants tend to have more severe and prolonged illnesses with relapsing fever [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/50\">",
"     50",
"    </a>",
"    ]. Congenital malformations as a consequence of relapsing fever have not been reported.",
"   </p>",
"   <p>",
"    A murine model of gestational relapsing fever infection found that infection during pregnancy causes intrauterine growth retardation, placental damage and inflammation, impaired fetal circulation, and decreased maternal hemoglobin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/51\">",
"     51",
"    </a>",
"    ]. In the murine model, spirochetes frequently crossed the maternal-fetal barrier leading to congenital infection. The model closely parallels human infection and provides potential mechanisms to account for the observed human pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREVENTION AND CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreasing louse and tick exposure is the major means of preventing relapsing fever. There is no vaccine for either LBRF or TBRF. The prospects for a successful vaccine are poor because a single strain can manifest a large number of serotypic identities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39336?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of relapsing fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Louse-borne relapsing fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;LBRF can be prevented by lowering the risk of louse infestation through improved personal hygiene, reduction of crowding, and better access to washing facilities. Clothing appears to be important in maintaining lice. Indigenous peoples who commonly wore clothes were observed to be at a higher risk of developing LBRF than those in the same geographic area who were generally naked.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Delousing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures for delousing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24339?source=see_link\">",
"     \"Pediculosis corporis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Tick-borne relapsing fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of TBRF can be reduced by construction of houses with concrete or sealed plank floors and without thatched roofs or mud walls. Log cabins pose a particular risk in North America when rodents nest in the roofs or beneath the house or porch. Interiors of buildings infested with Ornithodoros ticks can be sprayed with 2 percent benzene hydrochloride, 0.5 percent diazinon, or 0.5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    . Individuals usually are bitten by soft ticks while they are asleep in an infested dwelling, but the ticks may be observed during daytime exploration of a cave or crawling under a house. Domestic animals, such as pigs, can serve as reservoirs for infection, especially when they are kept adjacent to the living quarters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Postexposure treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of postexposure treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (200 mg on day one followed by 100 mg daily for four days) was demonstrated in a randomized trial of healthy individuals in Israel with suspected tick exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/52\">",
"     52",
"    </a>",
"    ]. Cases of TBRF were defined as a patient with fever and a positive blood smear. At three weeks, 10 cases of TBRF were diagnosed; all were in the placebo group (attack rate 22 percent). These findings support postexposure treatment for patients in endemic regions, since efficacy appeared to be 100 percent.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is not available, an alternative is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (500 mg four times daily for four days). These regimens can also be used after accidental inoculation with infected blood or culture medium in the laboratory, hospital, or clinic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343465099\">",
"    <span class=\"h1\">",
"     BORRELIA MIYAMOTOI INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Borrelia miyamotoi, a Borrelia species in the same taxonomic group as the agents of relapsing fever, has been found in some of the same tick vectors and rodent reservoirs as for Lyme disease agents in North America, Europe, and Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/53\">",
"     53",
"    </a>",
"    ]. While B. miyamotoi and the relapsing fever Borrelia species are not established as causes of Lyme disease, several reports have described clinical syndromes in patients with evidence of B. miyamotoi infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An influenza-like illness occurred in 46 patients in Russia who were infected with B. miyamotoi, a few of whom had a relapsing febrile illness or erythema migrans (EM) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/54\">",
"       54",
"      </a>",
"      ]. The possibility that the patients with EM were coinfected with a Borrelia species that is known to cause Lyme disease could not be excluded.",
"     </li>",
"     <li>",
"      Serologic testing to detect antibodies against B. miyamotoi GlpQ protein (an antigen that is not found in Lyme disease Borrelia species) was performed on archived samples collected between 1990 and 2010 from three groups of individuals in Lyme disease-endemic regions in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Group 1 consisted of 584 individuals in Rhode Island and Massachusetts who were healthy at the time of blood sampling. Group 2 consisted of 277 patients from southern New England who were evaluated for suspected Lyme disease. Group 3 consisted of 14 patients from southern New York with a virus-like illness who were evaluated at a Lyme disease clinic in the late spring or summer.",
"     </li>",
"     <li>",
"      The seroprevalence of antibodies against B. miyamotoi was 1.0 percent in group 1, 3.2 percent in group 2, and 21.0 percent in group 3. In one patient in group 2 and two patients in group 3, the antibody titer was at least four times as high in the convalescent serum samples as in the acute serum samples, suggesting that these patients were recently infected with B. miyamotoi. All three of these patients were immunocompetent.",
"     </li>",
"     <li>",
"      One patient in group 3 with recent B. miyamotoi seroconversion had no EM lesion and no laboratory evidence of human granulocytic anaplasmosis coinfection. This patient had a temperature of 39.4&deg;C, chills, sweats, a headache, neck stiffness, fatigue, myalgias, arthralgias, abdominal pain, a cough, a sore throat, and right inguinal lymphadenopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B. miyamotoi was detected by microscopy and the polymerase chain reaction from the cerebrospinal fluid of an elderly woman with follicular lymphoma in the northeastern United States who presented with progressive mental decline over four months [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15033/abstract/56\">",
"       56",
"      </a>",
"      ]. Her deficits included a decline in mental status, including increasing confusion, withdrawal from family interactions, episodes of not getting out of bed, wobbling gait, and difficulty hearing, accompanied by anorexia and a 30 pound weight loss. She was initially treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      , but was later switched to IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      to complete 30 days of therapy. Her mental status improved over the first three to five days of antimicrobial therapy and had returned to normal at the end of the 30-day course.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional study is necessary to further characterize the clinical syndromes caused by B. miyamotoi and to determine if this species can cause relapsing fever, an illness similar to Lyme disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distinct syndromes. The GlpQ antigen that was used in the study above is unique to B. miyamotoi. When B. miyamotoi infection is suspected, the GlpQ-based assay meant for relapsing fever agents may be useful, but its performance for this species remains to be determined.",
"   </p>",
"   <p>",
"    There is little experience with the treatment of B. miyamotoi infection, but it is likely that the organism has the same antibiotic susceptibilities as other Borrelia species. Until further information about treatment efficacy is available, treatment for suspected B. miyamotoi infection should follow the same guidelines as for Lyme disease, including parenteral therapy for central nervous system involvement (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"     \"Treatment of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1647008615\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapsing fever, caused by spirochetes of the Borrelia genus, is an arthropod-borne infection that occurs in two major forms: tick-borne (TBRF) and louse-borne (LBRF):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      TBRF is a zoonosis and is enzootic in many countries. The two main Borrelia spp involved in North America are B. hermsii (in the mountainous West) and B. turicatae (in the Southwest and South Central region). Other tick-borne species cause relapsing fever on other continents.",
"     </li>",
"     <li>",
"      LBRF is caused by B. recurrentis. It is principally a disease seen in the developing world; it is spread from person to person by the body louse and can occur in epidemics, including large ones involving millions of people. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapsing fever presents with the sudden onset of fever, punctuated by an intervening afebrile period, which occurs at least twice. The first fever episode ends by crisis, consisting of rigors, a further elevation in temperature, and increases in pulse and blood pressure, lasting approximately 15 to 30 minutes. The crisis phase is followed by profuse diaphoresis, falling temperature, and hypotension, which usually persists for several hours. Symptoms accompanying the fever can be protean and nonspecific. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epistaxis, petechiae, and ecchymoses are common during LBRF but not TBRF. Splenomegaly is also common. Neurologic findings are more common in tick-borne than louse-borne relapsing fever and are due to direct invasion of spirochetes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A mild to moderate normocytic anemia is common in patients with relapsing fever. Leukocyte counts are usually in the normal range or only slightly elevated, and there can be leukopenia during the crisis. Platelet counts can fall below",
"      <span class=\"nowrap\">",
"       50,000/microL.",
"      </span>",
"      Laboratory evidence of hepatitis can occur with elevated serum concentrations of unconjugated bilirubin and aminotransferases; the prothrombin and partial thromboplastin times may be moderately prolonged. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'General laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relapsing fever should be considered in a patient with the characteristic fever pattern, especially if the recurrent fevers are accompanied by the crisis phenomenon and an epidemiologic history of exposure to body lice or soft-bodied ticks in geographic areas where LBRF or TBRF fever is endemic. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thin and thick smears of blood are usually the first tests performed for suspected relapsing fever (",
"      <a class=\"graphic graphic_picture graphicRef63059 \" href=\"UTD.htm?22/37/23135\">",
"       picture 1",
"      </a>",
"      ). When relapsing fever is suspected but spirochetes are not directly visualized, laboratory confirmation of the clinical diagnosis requires techniques that are not available in most laboratories, namely animal inoculation and in vitro cultivation. Other techniques that can be used are the polymerase chain reaction and serologic testing. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of LBRF in adults, a single dose of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      (500 mg), oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (200 mg), or intramuscular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12661?source=see_link\">",
"       penicillin G procaine",
"      </a>",
"      (400,000 to 800,000 units) is effective. The corresponding doses for children are oral tetracycline at 12.5",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      oral doxycycline at 5",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      and intramuscular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      procaine at 200,000 to 400,000 units. When the patient cannot take tetracycline by mouth, the intravenous dose is 250 or 500 mg for adults. Since tetracycline is contraindicated in pregnant and nursing women and in children less than nine years old, in those who are allergic to penicillin, an alternative is oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      , 500 mg for adults and 12.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for children. Tetracycline is the preferred oral agent in those without a contraindication since it has better efficacy than erythromycin. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Louse-borne relapsing fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred treatment for TBRF in adults is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      (500 mg or 12.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally every six hours) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily), both for 10 days. When tetracyclines are contraindicated, the alternative is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      (500 mg or 12.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally every six hours) for 10 days. If a beta-lactam antibiotic is given, it should be administered intravenously, especially if central nervous system involvement is confirmed or suspected. Either intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      for 10 to 14 days is an appropriate regimen for patients with relapsing fever with neurologic involvement. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Tick-borne relapsing fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreasing louse and tick exposure is the major means of preventing relapsing fever. For patients in endemic regions, postexposure treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      can be used following a tick exposure. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prevention and control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Borrelia miyamotoi, a Borrelia species in the same taxonomic group as the agents of relapsing fever, has been found in some of the same tick vectors and rodent reservoirs as for Lyme disease agents in North America, Europe, and Asia. While B. miyamotoi and the relapsing fever species are not established as causes of Lyme disease, several reports have described clinical syndromes in patients with evidence of B. miyamotoi infection. (See",
"      <a class=\"local\" href=\"#H343465099\">",
"       'Borrelia miyamotoi infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is little experience with the treatment of B. miyamotoi infection, but it is likely that the organism has the same antibiotic susceptibilities as other Borrelia species. Until further information about treatment efficacy is available, treatment for suspected B. miyamotoi infection should follow the same guidelines as for Lyme disease, including parenteral therapy for central nervous system involvement (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H343465099\">",
"       'Borrelia miyamotoi infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Barbour AG. Relapsing fever. In: Tick-Borne Diseases of Humans, Goodman JL, Dennis DT, Sonenshine DE (Eds), ASM Press, Washington, DC 2005. p.268.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/2\">",
"      Barbour AG, Hayes SF. Biology of Borrelia species. Microbiol Rev 1986; 50:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/3\">",
"      Bryceson AD, Parry EH, Perine PL, et al. Louse-borne relapsing fever. Q J Med 1970; 39:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/4\">",
"      Dworkin MS, Schwan TG, Anderson DE Jr. Tick-borne relapsing fever in North America. Med Clin North Am 2002; 86:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/5\">",
"      Rijkels DF. Louse-borne relapsing fever in Ethiopia. Trop Geogr Med 1971; 23:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/6\">",
"      Southern, P, Sanford, J. Relapsing fever: A clinical and microbiological review. Medicine (Baltimore) 1969; 48:129.",
"     </a>",
"    </li>",
"    <li>",
"     Barbour, AG, Guo, BP. Pathogenesis of relapsing fever. In: Borrelia: Molecular biology, host interaction, and pathogenesis, Samuels, DS, Radolf, JD (Eds), Norwich, U.K., Caister Academic Press 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/8\">",
"      Cadavid D, Thomas DD, Crawley R, Barbour AG. Variability of a bacterial surface protein and disease expression in a possible mouse model of systemic Lyme borreliosis. J Exp Med 1994; 179:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/9\">",
"      Pennington PM, Allred CD, West CS, et al. Arthritis severity and spirochete burden are determined by serotype in the Borrelia turicatae-mouse model of Lyme disease. Infect Immun 1997; 65:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Acute respiratory distress syndrome in persons with tickborne relapsing fever--three states, 2004-2005. MMWR Morb Mortal Wkly Rep 2007; 56:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/11\">",
"      Dennis DT, Awoke S, Doberstyn EB, Fresh JW. Bleeding in louse-borne relapsing fever in Ethiopia; clinical and laboratory features in 29 patients. East Afr Med J 1976; 53:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/12\">",
"      Perine PL, Parry EH, Vukotich D, et al. Bleeding in louse-borne relapsing fever. I. Clinical studies in 37 patients. Trans R Soc Trop Med Hyg 1971; 65:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/13\">",
"      Wengrower D, Knobler H, Gillis S, Chajek-Shaul T. Myocarditis in tick-borne relapsing fever. J Infect Dis 1984; 149:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/14\">",
"      Cadavid D, Barbour AG. Neuroborreliosis during relapsing fever: review of the clinical manifestations, pathology, and treatment of infections in humans and experimental animals. Clin Infect Dis 1998; 26:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/15\">",
"      Ramos JM, Reyes F, Tesfamariam A, Malmierca E. Louse-borne relapsing fever and malaria co-infection in Ethiopia. Trop Doct 2007; 37:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/16\">",
"      Nordstrand A, Bunikis I, Larsson C, et al. Tickborne relapsing fever diagnosis obscured by malaria, Togo. Emerg Infect Dis 2007; 13:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/17\">",
"      Poulsen LW, Iversen G. Relapsing fever: a differential diagnosis to malaria. Scand J Infect Dis 1996; 28:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/18\">",
"      Goodman RL, Arndt KA, Steigbigel NH. Borrelia in Boston. JAMA 1969; 210:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/19\">",
"      Sciotto CG, Lauer BA, White WL, Istre GR. Detection of Borrelia in acridine orange-stained blood smears by fluorescence microscopy. Arch Pathol Lab Med 1983; 107:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/20\">",
"      Stoenner HG, Dodd T, Larsen C. Antigenic variation of Borrelia hermsii. J Exp Med 1982; 156:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/21\">",
"      Magnarelli LA, Anderson JF, Johnson RC. Cross-reactivity in serological tests for Lyme disease and other spirochetal infections. J Infect Dis 1987; 156:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/22\">",
"      Barbour AG, Maupin GO, Teltow GJ, et al. Identification of an uncultivable Borrelia species in the hard tick Amblyomma americanum: possible agent of a Lyme disease-like illness. J Infect Dis 1996; 173:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/23\">",
"      Chohan IS. Tick-borne relapsing fever in Kashmir: mice inoculation--a diagnostic method of choice. Indian J Pathol Bacteriol 1967; 10:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/24\">",
"      Schwan TG, Policastro PF, Miller Z, et al. Tick-borne relapsing fever caused by Borrelia hermsii, Montana. Emerg Infect Dis 2003; 9:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/25\">",
"      Barbour AG. Immunobiology of relapsing fever. Contrib Microbiol Immunol 1987; 8:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/26\">",
"      Kelly R. Cultivation of Borrelia hermsi. Science 1971; 173:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/27\">",
"      Stoenner HG. Biology of Borrelia hermsii in Kelly medium. Appl Microbiol 1974; 28:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/28\">",
"      Barbour AG. Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med 1984; 57:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/29\">",
"      Barbour AG. Laboratory aspects of Lyme borreliosis. Clin Microbiol Rev 1988; 1:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/30\">",
"      Dupont HT, La Scola B, Williams R, Raoult D. A focus of tick-borne relapsing fever in southern Zaire. Clin Infect Dis 1997; 25:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/31\">",
"      Brahim H, Perrier-Gros-Claude JD, Postic D, et al. Identifying relapsing fever Borrelia, Senegal. Emerg Infect Dis 2005; 11:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/32\">",
"      Halperin T, Orr N, Cohen R, et al. Detection of relapsing fever in human blood samples from Israel using PCR targeting the glycerophosphodiester phosphodiesterase (GlpQ) gene. Acta Trop 2006; 98:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/33\">",
"      Uhlmann EJ, Seed PC, Schwan TG, Storch GA. Tick-borne relapsing fever polymerase chain reaction of tick-borne relapsing fever caused by Borrelia hermsii. Pediatr Infect Dis J 2007; 26:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/34\">",
"      Dodge RW. Human serological response to louse-borne relapsing fever. Infect Immun 1973; 8:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/35\">",
"      Dworkin MS, Anderson DE Jr, Schwan TG, et al. Tick-borne relapsing fever in the northwestern United States and southwestern Canada. Clin Infect Dis 1998; 26:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/36\">",
"      Dworkin MS, Schwan TG, Anderson DE Jr, Borchardt SM. Tick-borne relapsing fever. Infect Dis Clin North Am 2008; 22:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/37\">",
"      Porcella SF, Raffel SJ, Schrumpf ME, et al. Serodiagnosis of Louse-Borne relapsing fever with glycerophosphodiester phosphodiesterase (GlpQ) from Borrelia recurrentis. J Clin Microbiol 2000; 38:3561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/38\">",
"      Barbour AG, Todd WJ, Stoenner HG. Action of penicillin on Borrelia hermsii. Antimicrob Agents Chemother 1982; 21:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/39\">",
"      Butler T, Jones PK, Wallace CK. Borrelia recurrentis infection: single-dose antibiotic regimens and management of the Jarisch-Herxheimer reaction. J Infect Dis 1978; 137:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/40\">",
"      Perine PL, Krause DW, Awoke S, McDade JE. Single-dose doxycycline treatment of louse-borne relapsing fever and epidemic typhus. Lancet 1974; 2:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/41\">",
"      Perine PL, Teklu B. Antibiotic treatment of louse-borne relapsing fever in Ethiopia: a report of 377 cases. Am J Trop Med Hyg 1983; 32:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/42\">",
"      Fekade D, Knox K, Hussein K, et al. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med 1996; 335:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/43\">",
"      Guerrier G, Doherty T. Comparison of antibiotic regimens for treating louse-borne relapsing fever: a meta-analysis. Trans R Soc Trop Med Hyg 2011; 105:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/44\">",
"      Horton JM, Blaser MJ. The spectrum of relapsing fever in the Rocky Mountains. Arch Intern Med 1985; 145:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/45\">",
"      CHERRY JK. The prevention and treatment of tick-borne relapsing fever with special reference to aureomycin and terramycin. Trans R Soc Trop Med Hyg 1955; 49:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/46\">",
"      Negussie Y, Remick DG, DeForge LE, et al. Detection of plasma tumor necrosis factor, interleukins 6, and 8 during the Jarisch-Herxheimer Reaction of relapsing fever. J Exp Med 1992; 175:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/47\">",
"      Remick DG, Negussie Y, Fekade D, Griffin G. Pentoxifylline fails to prevent the Jarisch-Herxheimer reaction or associated cytokine release. J Infect Dis 1996; 174:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/48\">",
"      Cooper PJ, Fekade D, Remick DG, et al. Recombinant human interleukin-10 fails to alter proinflammatory cytokine production or physiologic changes associated with the Jarisch-Herxheimer reaction. J Infect Dis 2000; 181:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/49\">",
"      ANDERSON TR, ZIMMERMAN LE. Relapsing fever in Korea; a clinicopathologic study of eleven fatal cases with special attention to association with Salmonella infections. Am J Pathol 1955; 31:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/50\">",
"      Ramos JM, Malmierca E, Reyes F, Tesfamariam A. Louse-borne relapsing fever in Ethiopian children: experience of a rural hospital. Trop Doct 2009; 39:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/51\">",
"      Larsson C, Andersson M, Guo BP, et al. Complications of pregnancy and transplacental transmission of relapsing-fever borreliosis. J Infect Dis 2006; 194:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/52\">",
"      Hasin T, Davidovitch N, Cohen R, et al. Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever. N Engl J Med 2006; 355:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/53\">",
"      Barbour AG, Bunikis J, Travinsky B, et al. Niche partitioning of Borrelia burgdorferi and Borrelia miyamotoi in the same tick vector and mammalian reservoir species. Am J Trop Med Hyg 2009; 81:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/54\">",
"      Platonov AE, Karan LS, Kolyasnikova NM, et al. Humans infected with relapsing fever spirochete Borrelia miyamotoi, Russia. Emerg Infect Dis 2011; 17:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/55\">",
"      Krause PJ, Narasimhan S, Wormser GP, et al. Human Borrelia miyamotoi infection in the United States. N Engl J Med 2013; 368:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15033/abstract/56\">",
"      Gugliota JL, Goethert HK, Berardi VP, Telford SR III. Meningoencephalitis from Borrelia miyamotoi in an immunocompromised patient. N Engl J Med 2013.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7897 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-9C20EB8C63-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15033=[""].join("\n");
var outline_f14_43_15033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1647008615\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Course of the fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Direct visualization procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Serologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Louse-borne relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Tick-borne relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Jarisch-Herxheimer reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREVENTION AND CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Louse-borne relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Delousing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Tick-borne relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Postexposure treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H343465099\">",
"      BORRELIA MIYAMOTOI INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1647008615\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7897\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7897|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/2/18478\" title=\"figure 1\">",
"      Temperature pattern in relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7897|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/37/23135\" title=\"picture 1\">",
"      Thin smear in relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7897|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/35/22078\" title=\"table 1\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39336?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24339?source=related_link\">",
"      Pediculosis corporis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_43_15034="Initial evaluation and management of suspected acute coronary syndrome in the emergency department";
var content_f14_43_15034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/43/15034/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/43/15034/contributors\">",
"     Thomas J Ryan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/43/15034/contributors\">",
"     Guy S Reeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/43/15034/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/43/15034/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/43/15034/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/43/15034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/43/15034/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/43/15034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of myocardial ischemia is most often acute chest discomfort. The goal of emergency department evaluation is to determine the cause of the chest discomfort and promptly initiate appropriate therapy. It is essential that initial assessment and management be rapid but methodical and evidence-based [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic evaluation emphasizes distinguishing among the following potential causes of chest pain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute coronary syndrome (myocardial infarction or unstable angina)",
"     </li>",
"     <li>",
"      Nonischemic chest pain, including potentially life-threatening conditions such as aortic dissection, pulmonary embolism, and esophageal rupture (",
"      <a class=\"graphic graphic_table graphicRef54763 \" href=\"UTD.htm?11/12/11467\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef53227 graphicRef77753 \" href=\"UTD.htm?41/41/42653\">",
"       table 2A-B",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of acute coronary ischemia depends upon the characteristics of the chest pain, specific associated symptoms, abnormalities on electrocardiogram (ECG), and levels of serum markers of cardiac injury. A patient with a possible acute coronary syndrome (ACS) should be treated rapidly. Thus, initial management steps must be undertaken before or during the time the diagnosis is being established.",
"   </p>",
"   <p>",
"    The initial management of the patient likely to have an ACS will be reviewed here. Discussions of related topics are found separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20090?source=see_link\">",
"       \"Evaluation of chest pain in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=see_link\">",
"       \"Evaluation of the adult with dyspnea in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"       \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31961?source=see_link\">",
"       \"Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Cardiology (ACC) and the American Heart Association (AHA) recommend that all hospitals establish multidisciplinary teams to develop guideline-based, institution-specific written protocols for triaging and managing patients who present with symptoms suggestive of myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Immediate cardiology consultation should be available for cases in which the initial diagnosis and treatment plan are unclear or are not covered directly by the protocol. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMMEDIATE ED INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the emergency department (ED), patients presenting with chest pain should be rapidly evaluated to determine if their symptoms are suggestive of acute ischemia, or some other potentially life-threatening illness. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Clinical presentation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20090?source=see_link\">",
"     \"Evaluation of chest pain in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=see_link\">",
"     \"Evaluation of the adult with dyspnea in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If acute coronary syndrome (ACS) is the leading diagnosis, initial assessment and interventions must be performed rapidly. The attached algorithm provides a simple approach to risk stratification while the table provides a concise outline of the immediate interventions needed to manage ST elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina (",
"    <a class=\"graphic graphic_algorithm graphicRef56813 \" href=\"UTD.htm?2/55/2930\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75032 \" href=\"UTD.htm?33/25/34206\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Caution should be employed in evaluating possible ACS in women, diabetics, and the elderly, who are more likely to present with \"atypical\" symptoms even in the presence of acute coronary ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Atypical symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The institution's specific chest pain protocol should be implemented if the history or symptoms are suggestive of acute ischemia. The time for initial assessment, including ECG, and preliminary management of a patient with possible acute coronary ischemia is ideally 10 minutes from presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/6\">",
"     6",
"    </a>",
"    ]. Data from a national registry have shown that ECG acquisition is frequently delayed, and that women are significantly less likely to have ECGs performed within the recommended 10 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the initial assessment phase, the following steps should be accomplished for any patient at significant risk for ACS:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Airway, breathing, and circulation assessed",
"     </li>",
"     <li>",
"      Preliminary history and examination obtained",
"     </li>",
"     <li>",
"      12-lead ECG interpreted",
"     </li>",
"     <li>",
"      Resuscitation equipment brought to the bedside",
"     </li>",
"     <li>",
"      Cardiac monitor attached to patient",
"     </li>",
"     <li>",
"      Oxygen given",
"     </li>",
"     <li>",
"      IV access and blood work obtained",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      162 to 325 mg given",
"     </li>",
"     <li>",
"      Nitrates and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      given (unless contraindicated)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Initial history and exam",
"      </strong>",
"      &ndash; Obtain a brief history and perform a focused physical examination [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/6\">",
"       6",
"      </a>",
"      ]. Important elements of the history include confirmation of the presenting symptoms, characteristics of the pain and important associated symptoms, past history of or risk factors for cardiovascular disease, and potential contraindications to thrombolytic therapy (",
"      <a class=\"graphic graphic_table graphicRef68784 \" href=\"UTD.htm?23/16/23820\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical presentation'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The examination should include assessment of hemodynamic status and a screening neurologic examination, especially if thrombolysis is entertained as a potential therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Physical examination'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The history should also address potentially emergent noncardiac causes of chest pain, such as acute aortic dissection, pulmonary embolism, tension pneumothorax, perforating peptic ulcer, and esophageal rupture (",
"      <a class=\"graphic graphic_table graphicRef53227 graphicRef77753 \" href=\"UTD.htm?41/41/42653\">",
"       table 2A-B",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20090?source=see_link\">",
"       \"Evaluation of chest pain in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Twelve-lead ECG",
"      </strong>",
"      &ndash; A 12-lead ECG should be obtained in all patients with possible coronary ischemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'ECG Assessment'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The 12-lead ECG provides the basis for initial diagnosis and management and should immediately be shown to an emergency physician for interpretation.",
"      <br/>",
"      <br/>",
"      The initial ECG is often",
"      <strong>",
"       NOT",
"      </strong>",
"      diagnostic in patients with ACS. The ECG should be repeated at 5 to 10 minute intervals if the initial study is not diagnostic but the patient remains symptomatic and high clinical suspicion for ACS persists [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiac monitor",
"      </strong>",
"      &ndash; The patient should be placed on a cardiac monitor, with emergency resuscitation equipment (including a defibrillator and airway equipment) nearby.",
"     </li>",
"     <li>",
"      <strong>",
"       Supplemental oxygen",
"      </strong>",
"      &ndash; Supplemental oxygen should be initiated to maintain oxygen saturation above 90 percent.",
"     </li>",
"     <li>",
"      <strong>",
"       Intravenous access",
"      </strong>",
"      &ndash; Intravenous access should be established, with blood drawn for initial laboratory work, including cardiac biomarkers, electrolytes, indices of coagulation and renal function, and serum lipid profile [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cardiac biomarkers'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      &ndash; All patients with suspected ACS should be given aspirin in a dose of 325 mg to chew and swallow, unless there is a compelling contraindication (eg, history of anaphylactic reaction) or it has been taken prior to presentation. Despite its well demonstrated benefit, aspirin remains underutilized in the setting of ACS [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"       \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sublingual nitrates",
"      </strong>",
"      &ndash; In most cases, sublingual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      should be administered at a dose of 0.4 mg every five minutes for a total of three doses, after which an assessment of blood pressure and pain relief should guide the need for intravenous nitroglycerin [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Before this is done, all patients should be questioned about the use of phosphodiesterase-5 inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      (Viagra),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      (Levitra), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      (Cialis); nitrates are contraindicated if these drugs have been used in the last 24 hours (or perhaps as long as 36 hours with tadalafil) because of the propensity to cause potentially severe hypotension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24566?source=see_link\">",
"       \"Nitrates in the management of acute coronary syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link&amp;anchor=H15#H15\">",
"       \"Sexual activity in patients with heart disease\", section on 'Treatment of sexual dysfunction'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Extreme care should also be taken before giving nitrates in the setting of an inferior myocardial infarction with possible involvement of the right ventricle (",
"      <a class=\"graphic graphic_waveform graphicRef82739 \" href=\"UTD.htm?42/21/43354\">",
"       waveform 1",
"      </a>",
"      ). In this setting, patients are dependent upon preload to maintain cardiac output, and nitrates can cause severe hypotension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link\">",
"       \"Right ventricular myocardial infarction\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Pain that responds to sublingual nitroglycerin is frequently thought to have a cardiac etiology or to be due to esophageal spasm. However, pain relief with nitroglycerin in an acute care setting is",
"      <strong>",
"       not",
"      </strong>",
"      helpful in distinguishing cardiac from noncardiac chest pain [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/10\">",
"       10",
"      </a>",
"      ]. In a study of 459 patients who presented to an emergency department with chest pain and were admitted to the hospital, the percentage of patients who had relief of chest pain with nitroglycerin was similar among the 141 patients with ACS and the 275 patients without active coronary disease (35 versus 41 percent experienced relief) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20090?source=see_link\">",
"       \"Evaluation of chest pain in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       Morphine",
"      </a>",
"      &ndash; Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine sulfate",
"      </a>",
"      at an initial dose of 2 to 4 mg, with increments of 2 to 8 mg, repeated at 5 to 15 minute intervals, should be given for the relief of chest pain and anxiety [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/6\">",
"       6",
"      </a>",
"      ]. Morphine can reduce sympathetic stimulation caused by pain and anxiety, thereby decreasing cardiac workload and risks associated with excess catecholamines. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4507342\">",
"    <span class=\"h1\">",
"     DETERMINING WHO NEEDS AN ELECTROCARDIOGRAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, a resting electrocardiogram (ECG) should be obtained in adults with chest pain that does not have an obvious noncardiac cause. However, identifying at triage or early in the ED evaluation which patients should be evaluated with an ECG is sometimes difficult. As one important example, a substantial number of patients ultimately diagnosed with an acute coronary syndrome (ACS), particularly older patients, women, and diabetics, present with complaints other than chest discomfort. Such presentations are discussed in detail separately. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Atypical symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One research group has proposed the following rule for identifying patients at high risk for ST elevation myocardial infarction (STEMI) who should be evaluated with an ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any patient over 30 with chest pain",
"     </li>",
"     <li>",
"      Any patient over 50 with any of the following: dyspnea, altered mental status, upper extremity pain, syncope, or weakness",
"     </li>",
"     <li>",
"      Any patient over 80 with abdominal pain, nausea, or vomiting",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This rule was derived and validated using information from over 3 million ED visits included in a state-wide health surveillance database. Included in the database were 6,464 cases of STEMI diagnosed during 2007 to 2008 that provided the dataset for the study. When applied to the validation sample (3,294 STEMI cases), the rule had a sensitivity of 91.9 percent (95% CI 90.9-92.8) and a specificity of 76.2 percent (95% CI 76.1-76.2).",
"   </p>",
"   <p>",
"    This proposed rule should not replace clinical judgement (in fact the authors encourage clinicians to obtain an ECG based upon such judgement). As an example, a patient in whom a noncardiac diagnosis is likely (eg, younger patient with obvious zoster (shingles) lesions and no other symptoms) may not need an ECG. Nevertheless, this study provides some evidence for clinicians trying to devise appropriate triage protocols for the ED or to determine in which patients, including those not presenting with chest pain, an ECG assessment is needed.",
"   </p>",
"   <p>",
"    Prospective validation of this decision rule is needed before widespread adoption can be recommended. Among the rule&rsquo;s limitations are its relatively low sensitivity and the age cut-offs, which may be too high in some settings. It is worth reiterating the importance of paying close attention to older patients, diabetics, and women with symptoms consistent with ACS and using a low threshold for obtaining an ECG in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ECG ASSESSMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8275033\">",
"    <span class=\"h2\">",
"     Initial interpretation and criteria for ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific approaches to patients judged to have definite or probable acute coronary syndrome (ACS) based upon a targeted history and physical examination are initially guided by the accompanying 12-lead electrocardiogram (ECG). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians must beware that the initial ECG is often",
"    <strong>",
"     NOT",
"    </strong>",
"    diagnostic in patients with ACS. In patients without a clear diagnosis but at risk for ACS, ECGs should be repeated at frequent intervals until the patient's chest pain resolves or a definitive diagnosis is made. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Importance of serial ECGs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When present, ECG abnormalities are an early sign of myocardial ischemia. Criteria for the two major categories of electrocardiographic manifestations of acute myocardial ischemia are listed here [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Findings consistent with ST elevation myocardial infarction (STEMI)",
"      </strong>",
"      : New ST elevation at the J point in two anatomically contiguous leads using the following diagnostic thresholds: &ge;0.1 mV (1 mm) in all leads other than V2-V3, where the following diagnostic thresholds apply: &ge;0.2 mV (2 mm) in men 40 years; &ge;0.25 mV (2.5 mm) in men &lt;40 years, or &ge;0.15 mV (1.5 mm) in women.",
"     </li>",
"     <li>",
"      <strong>",
"       Findings consistent with Non ST elevation myocardial infarction or unstable angina",
"      </strong>",
"      : New horizontal or down-sloping ST depression &ge;0.05 mV (0.5 mm) in two anatomically contiguous leads",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      T inversion &ge;0.1 mV (1 mm) in two anatomically contiguous leads with prominent R wave or",
"      <span class=\"nowrap\">",
"       R/S",
"      </span>",
"      ratio &gt;1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Localization of ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG leads are more helpful in localizing regions of transmural than subendocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. The anatomic location of a transmural infarct is determined by which ECG leads show ST elevation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased T wave positivity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Anterior wall ischemia",
"      </strong>",
"      &ndash; Two or more of the precordial leads (V1-V6) (",
"      <a class=\"graphic graphic_waveform graphicRef81914 graphicRef62059 \" href=\"UTD.htm?0/5/84\">",
"       waveform 2A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Anteroseptal ischemia",
"      </strong>",
"      &ndash; Leads V1 to V3 (",
"      <a class=\"graphic graphic_waveform graphicRef75683 \" href=\"UTD.htm?39/58/40874\">",
"       waveform 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Apical or lateral ischemia",
"      </strong>",
"      &ndash; Leads aVL and I, and leads V4 to V6 (",
"      <a class=\"graphic graphic_waveform graphicRef82413 \" href=\"UTD.htm?41/53/42842\">",
"       waveform 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Inferior wall ischemia",
"      </strong>",
"      &ndash; Leads II, III, and aVF (",
"      <a class=\"graphic graphic_waveform graphicRef82739 \" href=\"UTD.htm?42/21/43354\">",
"       waveform 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Right ventricular ischemia",
"      </strong>",
"      &ndash; Right-sided precordial leads",
"     </li>",
"     <li>",
"      <strong>",
"       Posterior wall ischemia",
"      </strong>",
"      &ndash; Posterior precordial leads",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The right-sided leads V4R, V5R, and V6R should be obtained if there is evidence of inferior wall ischemia, demonstrated by ST elevation in leads II, III, and aVF. &nbsp;",
"   </p>",
"   <p>",
"    The posterior leads V7, V8, and V9 may also be helpful if there is evidence of posterior wall ischemia, as suggested by prominent R waves and ST depressions in leads V1 and V2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Importance of serial ECGs",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the initial ECG is not diagnostic but the patient remains symptomatic and clinical suspicion for ACS remains high, the ECG should be repeated at least every 20 to 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients whose repeat ECGs are diagnostic for or strongly suggestive of either STEMI or NSTEMI, should be managed for those diagnoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial ECG is often",
"    <strong>",
"     NOT",
"    </strong>",
"    diagnostic in patients with ACS. In two series, the initial ECG was nondiagnostic in 45 percent and normal in 20 percent of patients subsequently shown to have an acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/8,15\">",
"     8,15",
"    </a>",
"    ]. In the early hours of infarction, peaked, hyperacute T waves may be the only abnormality. In addition to evolution of the ECG, an uncommon source of error is pseudonormalization of baseline T wave inversion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinicians assume that an ECG obtained while the patient is experiencing chest pain that fails to show evidence of ischemia rules out the possibility of ACS. This assumption is false, as demonstrated by two prospective observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     LBBB or pacemaker",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both left bundle branch block (LBBB), which is present in approximately 7 percent of patients with an acute MI, and pacing can interfere with the electrocardiographic diagnosis of coronary ischemia. Another problem is that approximately one-half of patients with LBBB and an acute MI do not have chest pain as a symptom of their ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/19\">",
"     19",
"    </a>",
"    ]. As a result, patients with LBBB are much less likely to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blockers, and reperfusion therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/20\">",
"     20",
"    </a>",
"    ], particularly if they present without chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/19\">",
"     19",
"    </a>",
"    ]. Similar observations have been made in patients with a paced rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Careful evaluation of the ECG may show some evidence of ACS in patients with these abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9431?source=see_link\">",
"     \"Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm\"",
"    </a>",
"    .) However, the clinical history and cardiac enzymes are of primary importance in diagnosing an ACS in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain characteristics of the patient's chest discomfort and associated symptoms increase the likelihood of ACS, while others make the diagnosis unlikely. Important characteristics are highlighted below. A more detailed discussion is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, older patients, diabetics, and women are more likely to present with symptoms such as dyspnea, weakness, nausea and vomiting, palpitations, and syncope, and may not manifest chest discomfort. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Atypical symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ischemic chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic pain has a number of features that tend to distinguish it from noncardiac pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. These characteristics are described below using the OPQRST mnemonic. Symptoms associated with the highest relative risk of myocardial infarction (MI) include radiation to an upper extremity, particularly when there is radiation to both arms, and pain associated with diaphoresis or with nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. An important question is whether current pain is reminiscent of prior MI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Onset",
"      </strong>",
"      &ndash; Ischemic pain is typically gradual in onset, although the intensity of the discomfort may wax and wane.",
"     </li>",
"     <li>",
"      <strong>",
"       Provocation and palliation",
"      </strong>",
"      &ndash; Ischemic pain is generally provoked by an activity, such as exercise, which increases cardiac oxygen demand [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Ischemic pain does not change with respiration or position. It may or may not respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      and, if there is improvement, this may only be temporary. Relief of pain following the administration of therapeutic interventions (eg, nitroglycerin, \"GI cocktail\" of viscous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and antacid) does",
"      <strong>",
"       NOT",
"      </strong>",
"      reliably distinguish nonischemic from ischemic chest pain [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/25-27\">",
"       25-27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Quality",
"      </strong>",
"      &ndash; Ischemic pain is often characterized more as a discomfort than pain, and it may be difficult for the patient to describe. Terms frequently used by patients include squeezing, tightness, pressure, constriction, crushing, strangling, burning, heartburn, fullness in the chest, band-like sensation, knot in the center of the chest, lump in throat, ache, heavy weight on chest (elephant sitting on chest), like a bra too tight, and toothache (when there is radiation to the lower jaw). It is generally not described as sharp, fleeting, knife-like, stabbing, or pins and needles-like [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/23\">",
"       23",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Increased pain severity does not appear to correlate with an increased likelihood of acute MI [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/28\">",
"       28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In some cases, the patient cannot qualify the nature of the discomfort but places his or her clenched fist in the center of the chest, known as the \"Levine sign.\"",
"     </li>",
"     <li>",
"      <strong>",
"       Radiation",
"      </strong>",
"      &ndash; Ischemic pain often radiates to other parts of the body including the upper abdomen (epigastrium), shoulders, arms (upper and forearm), wrist, fingers, neck and throat, lower jaw and teeth (but not upper jaw), and not infrequently to the back (specifically the interscapular region). The old dictum that \"pain above the nose or below the navel is rarely cardiac in origin\" still holds. Pain radiating to the upper extremities is highly suggestive of ischemic pain [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/22-24\">",
"       22-24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Site",
"      </strong>",
"      &ndash; Ischemic pain is not felt in one specific spot, but rather it is a diffuse discomfort that may be difficult to localize. The patient often indicates the entire chest, rather than localizing it to a specific area by pointing a single finger.",
"     </li>",
"     <li>",
"      <strong>",
"       Time course",
"      </strong>",
"      &ndash; Angina is usually brief (two to five minutes) and is relieved by rest or with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      . In comparison, patients with an acute coronary syndrome (ACS) may have chest pain at rest, and the duration is variable but generally lasts longer than 30 minutes. Classic anginal pain lasting more than 20 minutes suggests ACS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Historical features increasing likelihood of ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical features that increase the likelihood of ACS include the following (",
"    <a class=\"graphic graphic_table graphicRef51235 \" href=\"UTD.htm?2/29/2524\">",
"     table 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a prior history of ACS have a significantly increased risk of recurrent ischemic events [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prior history of other vascular disease is associated with a risk of cardiac ischemic events comparable to that seen with a prior history of ACS [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Risk factors for ACS, particularly age, male sex, diabetes, hypertension, hyperlipidemia, and cigarette smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"       \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"      </a>",
"      .)&nbsp;",
"     </li>",
"     <li>",
"      Recent cocaine use [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic pain is often associated with other symptoms. The most common is shortness of breath, which may reflect mild pulmonary congestion resulting from ischemia-mediated diastolic dysfunction. Other symptoms may include belching, nausea, indigestion, vomiting, diaphoresis, dizziness, lightheadedness, clamminess, and fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Noncardiac chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific chest pain characteristics can be used to help differentiate cardiac from noncardiac causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20090?source=see_link\">",
"     \"Evaluation of chest pain in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In two systematic reviews, the following characteristics were found to be more typical of",
"    <strong>",
"     NON",
"    </strong>",
"    ischemic chest discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/22,33\">",
"     22,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pleuritic pain, sharp or knife-like pain related to respiratory movements or cough",
"     </li>",
"     <li>",
"      Primary or sole location in the mid or lower abdominal region",
"     </li>",
"     <li>",
"      Any discomfort localized with one finger",
"     </li>",
"     <li>",
"      Any discomfort reproduced by movement or palpation",
"     </li>",
"     <li>",
"      Constant pain lasting for days",
"     </li>",
"     <li>",
"      Fleeting pains lasting for a few seconds or less",
"     </li>",
"     <li>",
"      Pain radiating into the lower extremities or above the mandible",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, some patients with ACS present with so-called \"atypical\" chest pain. This was illustrated in the Multicenter Chest Pain Study in which acute ischemia was diagnosed in 22 percent of patients who presented with sharp or stabbing pain and 13 percent who presented with pleuritic-type pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Atypical symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, some patients who appear to have a noncardiac cause of chest pain have other serious conditions including acute aortic dissection, pulmonary embolism, tension pneumothorax, myocarditis, perforating peptic ulcer, and esophageal rupture (",
"    <a class=\"graphic graphic_table graphicRef54629 \" href=\"UTD.htm?5/17/5406\">",
"     table 6",
"    </a>",
"    ). It is essential to consider these alternate diagnoses to avoid potentially dangerous errors in management, such as the administration of thrombolytic therapy to a patient with an aortic dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ATYPICAL SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with acute coronary syndrome (ACS) present with atypical symptoms rather than chest pain. In a review of over 430,000 patients with confirmed acute myocardial infarction (MI) from the National Registry of Myocardial Infarction II, one-third had no chest pain on presentation to the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/35\">",
"     35",
"    </a>",
"    ]. These patients often present with symptoms such as dyspnea alone, weakness, nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting, palpitations, syncope, or cardiac arrest. They are more likely to be older, diabetic, and women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/23,35-37\">",
"     23,35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41113?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of coronary heart disease in women\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'Silent ischemia and infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absence of chest pain has important implications for therapy and prognosis. In the Registry report, patients without chest pain were much less likely to be diagnosed with a confirmed MI on admission (22 versus 50 percent in those with chest pain) and were less likely to be treated with appropriate medical therapy and to receive thrombolytic therapy or primary percutaneous coronary intervention (PCI) (25 versus 74 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/35\">",
"     35",
"    </a>",
"    ]. Not surprisingly, these differences were associated with an increase in in-hospital mortality (23.3 versus 9.3 percent, adjusted odds ratio 2.21, 95% CI 2.17-2.26).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial physical examination should focus on findings that permit rapid triage and aid in immediate diagnosis and management and should include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Responsiveness, airway, breathing and circulation &ndash; In patients in respiratory or cardiorespiratory arrest, the appropriate resuscitation algorithms should be followed (",
"      <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"       \"Advanced cardiac life support (ACLS) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evidence of systemic hypoperfusion (hypotension; tachycardia; impaired cognition; cool, clammy, pale, ashen skin) &ndash; Cardiogenic shock complicating acute MI requires aggressive evaluation and management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"       \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evidence of heart failure (jugular venous distention, new or worsening pulmonary crackles, hypotension, tachycardia, new S3 gallop, new or worsening MR murmur) &ndash; Aggressive management is needed for patients with heart failure complicating an acute MI, depending upon the severity of the heart failure and the presence of other risk factors (",
"      <a class=\"graphic graphic_table graphicRef65592 \" href=\"UTD.htm?3/59/4027\">",
"       table 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A screening neurologic examination should be performed to assess for focal lesions or cognitive deficits that might preclude safe use of thrombolytic therapy (",
"      <a class=\"graphic graphic_table graphicRef68784 \" href=\"UTD.htm?23/16/23820\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"       \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CARDIAC BIOMARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial serum biomarkers (sometimes referred to as cardiac enzymes) of acute myocardial damage, such as troponin T and I, are essential for confirming the diagnosis of infarction. They should be obtained in any patient at significant risk of ACS. The use of biomarkers is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2537?source=see_link\">",
"     \"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     ST elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients who meet the criteria for ST elevation myocardial infarction (STEMI) is discussed separately. The accompanying table provides a concise summary of the immediate treatment interventions needed in these patients (",
"    <a class=\"graphic graphic_table graphicRef75032 \" href=\"UTD.htm?33/25/34206\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'ECG Assessment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Selection and implementation of the optimal reperfusion strategy is the most important step in the management of STEMI and is discussed separately. Reperfusion therapy, whether percutaneous coronary intervention (PCI) or thrombolytics, should",
"    <strong>",
"     NOT",
"    </strong>",
"    await the result of cardiac biomarker measurement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid implementation of primary PCI is more likely to be achieved if the hospital protocol involves immediate activation of the PCI team by the emergency clinician and immediate transfer of the patient to the catheterization laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Non-ST elevation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Diagnosis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose presentation raises concern for coronary ischemia but who do not manifest ST elevations on ECG are considered to have unstable angina (UA) or a non-ST elevation myocardial infarction (NSTEMI). The management of patients with UA or NSTEMI is discussed separately. The accompanying table provides a concise summary of the immediate treatment interventions needed in these patients (",
"    <a class=\"graphic graphic_table graphicRef75032 \" href=\"UTD.htm?33/25/34206\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'ECG Assessment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    UA and NSTEMI comprise part of the spectrum of ACS. Angina is considered unstable if it presents in any of the following three ways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rest angina, generally lasting longer than 20 minutes",
"     </li>",
"     <li>",
"      New onset angina that markedly limits physical activity",
"     </li>",
"     <li>",
"      Increasing angina that is more frequent, lasts longer, or occurs with less exertion than previous angina",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    NSTEMI is distinguished from UA by the presence of elevated serum biomarkers. ST segment elevations and Q waves are absent in both UA and NSTEMI. As a result, UA and NSTEMI are frequently indistinguishable at initial evaluation since an elevation in serum biomarkers is usually not detectable for four to six hours after an MI, and at least 12 hours are required to detect elevations in all patients. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Cardiac biomarkers'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=see_link\">",
"     \"Classification of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombolytic therapy should",
"    <strong>",
"     NOT",
"    </strong>",
"    be administered to patients with UA or NSTEMI unless subsequent ECG monitoring documents ST segment elevations that persist [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An aggressive approach to reperfusion using PCI is best suited for patients with an elevated troponin level or a TIMI risk score &ge;5 or possibly other high-risk features. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'High-risk patient'",
"    </a>",
"    below.) For patients at lower risk, approaches vary based upon hospital protocol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both patient outcomes and the effectiveness of specific treatments for patients with UA and NSTEMI vary according to the presence or absence of high-risk features in their presentation. This fact underscores the importance of accurate risk stratification in the emergency department. Risk stratification is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H3#H3\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'Immediate high-risk patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'Early risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cardiac arrhythmias during ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disturbances of cardiac rhythm during an MI are usually detected by cardiac monitor rather than by physical examination or 12-lead ECG (",
"    <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"     algorithm 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sustained ventricular tachyarrhythmias in the peri-infarction period must be treated immediately because of their deleterious effect on cardiac output, possible exacerbation of myocardial ischemia, and the risk of deterioration into ventricular fibrillation (",
"      <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"       \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While supraventricular tachyarrhythmias in the peri-infarction period may pose less immediate risk of cardiac arrest, the management of such arrhythmias is important because any tachycardia can increase myocardial oxygen demand, thereby exacerbating ischemia and possibly decreasing cardiac output (",
"      <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"       algorithm 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=see_link\">",
"       \"Supraventricular arrhythmias after myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bradyarrhythmias occurring early in the setting of an inferior wall MI (within the first 24 hours) may respond to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef63919 \" href=\"UTD.htm?1/16/1280\">",
"       algorithm 4",
"      </a>",
"      ). Later bradyarrhythmias, wide QRS-complex bradyarrhythmias, and those occurring in the setting of an anterior wall MI may require temporary pacemaker placement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=see_link\">",
"       \"Conduction abnormalities after myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Disposition of patient without STEMI",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients without STEMI, the ECG remains a critical component in determining risk for adverse outcomes in ACS. The patient's hemodynamic status, serum biomarkers, and historical risk factors, as well as available hospital resources, should also be used to determine appropriate disposition. The utility of epidemiologic risk factors in determining acute, individual risk has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     High-risk patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient has a high-risk ACS if ST segment depression (&ge;0.05 mV [0.5 mm]) is present in two or more contiguous leads, elevated serum biomarkers,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the TIMI risk score is &ge;5. This patient is typically admitted to an intensive care unit, coronary care unit, or monitored cardiac unit depending upon the persistence of symptoms and evidence of hemodynamic compromise. Those with persistent pain or hemodynamic compromise generally undergo urgent angiography and revascularization. Others with resolution of symptoms and stable hemodynamics are typically referred for early elective angiography and revascularization if appropriate.",
"   </p>",
"   <p>",
"    If there is no ST segment elevation or depression or new LBBB, regardless of the presence or absence of Q waves, the patient with definite or probable ACS should still be admitted to a monitored care unit for further evaluation. Those patients manifesting high-risk features either on presentation or during their emergency department course should be admitted and considered for early PCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H3#H3\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'Immediate high-risk patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'Early risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Low and moderate risk patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management, including methods for risk assessment, of patients who have no ECG changes and normal serum biomarkers, but are still considered to be at low or moderate risk for ACS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31961?source=see_link\">",
"     \"Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     IMPACT OF MISSED DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In different studies, 1.9 to 4 percent of patients with an ACS are mistakenly discharged from the emergency department (ED) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/36,42,43\">",
"     36,42,43",
"    </a>",
"    ]; these patients have an increase in short-term mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/36,42\">",
"     36,42",
"    </a>",
"    ]. This issue was best evaluated in a review of 10,689 patients who presented to the ED with symptoms suggesting acute coronary ischemia: 8 percent had an acute MI and 9 percent had unstable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/36\">",
"     36",
"    </a>",
"    ]. Among the patients with an ACS, 2.2 percent were mistakenly discharged from the emergency department. Atypical presentation most frequently led to missed diagnosis. The patients with missed MI had the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Women less than 55 years of age",
"     </li>",
"     <li>",
"      Nonwhite",
"     </li>",
"     <li>",
"      Shortness of breath as the major presenting symptom",
"     </li>",
"     <li>",
"      Normal or nondiagnostic ECG",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Misreading of the ECG was an infrequent problem. There was a nonsignificant trend toward an increased risk-adjusted 30-day mortality ratio for patients who were not hospitalized (1.9 and 1.7 in the patients with MI and unstable angina, respectively).",
"   </p>",
"   <p>",
"    A similar frequency of missed diagnosis was noted in a second report in which 1.9 percent of 1050 patients with an acute MI were mistakenly discharged from the ED [",
"    <a class=\"abstract\" href=\"UTD.htm?14/43/15034/abstract/43\">",
"     43",
"    </a>",
"    ]. Among these 20 patients, five had missed ST elevation and seven were discharged with a diagnosis of ACS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OBSERVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients without clear evidence of acute coronary syndrome (ACS) by clinical history, ECG, or biomarker measurement ultimately sustain a myocardial infarction (MI) or develop unstable angina. Therefore, patients with an uncertain diagnosis after initial assessment require further observation and evaluation. The management of such patients, including the use of chest pain observation units, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31961?source=see_link\">",
"     \"Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     REST AND STRESS IMAGING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rest imaging tests, including radionuclide myocardial perfusion imaging (rMPI) and echocardiography, may be of value in the evaluation of patients who have persistent chest pain suggestive of an acute coronary syndrome (ACS), a nondiagnostic ECG, and initially or serially negative cardiac biomarkers. Some patients in whom the chest pain has resolved may undergo stress testing with or without imaging. Use of these diagnostic tests is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29578?source=see_link\">",
"     \"Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to detecting myocardial dysfunction or ischemia consistent with the diagnosis of an MI, imaging studies such as a contrast-enhanced chest CT scan, or cardiovascular magnetic resonance imaging can be used to differentiate an MI from an aortic dissection in patients for whom this distinction is initially unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40643584\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest discomfort can be caused by a number of life-threatening conditions, including pulmonary embolism, aortic dissection, and pneumothorax, and emergency clinicians must avoid premature diagnosis of acute coronary syndrome (ACS). The evaluation of chest pain in the emergency department is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20090?source=see_link\">",
"       \"Evaluation of chest pain in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If acute coronary syndrome (ACS) is the leading diagnosis, initial assessment and interventions must be performed rapidly to minimize potential injury to the myocardium. During the initial assessment phase, the following steps should be accomplished for any patient at significant risk for ACS:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Airway, breathing, and circulation assessed",
"     </li>",
"     <li>",
"      Preliminary history and examination obtained",
"     </li>",
"     <li>",
"      12-lead electrocardiogram (ECG) interpreted",
"     </li>",
"     <li>",
"      Resuscitation equipment brought to the bedside",
"     </li>",
"     <li>",
"      Cardiac monitor attached to patient",
"     </li>",
"     <li>",
"      Oxygen given",
"     </li>",
"     <li>",
"      IV access and blood work obtained",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      162 to 325 mg given",
"     </li>",
"     <li>",
"      Nitrates and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      given (unless contraindicated) (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Immediate ED interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial ECG is often",
"      <strong>",
"       NOT",
"      </strong>",
"      diagnostic in patients with ACS. In patients without a clear diagnosis but at risk for ACS, ECGs should be repeated at frequent intervals (every 10 to 15 minutes) until the patient's chest pain resolves or a definitive diagnosis is made. ECG assessment is described in the text. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'ECG Assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain characteristics of the patient's chest discomfort and associated symptoms increase the likelihood of ACS, while others make the diagnosis unlikely. These are described in the text. Caution should be employed in evaluating possible ACS in women, diabetics, and the elderly, who are more likely to present with \"atypical\" symptoms even in the presence of acute coronary ischemia. Of note, relief of symptoms following the administration of therapeutic interventions (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , \"GI cocktail\" of viscous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and antacid) does",
"      <strong>",
"       NOT",
"      </strong>",
"      reliably distinguish nonischemic from ischemic chest pain. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Atypical symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial physical examination should focus on findings that permit rapid triage and aid in immediate diagnosis and management. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The attached algorithm provides a simple approach to risk stratification while the table provides a concise outline of the immediate interventions needed to manage ST elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina (",
"      <a class=\"graphic graphic_algorithm graphicRef56813 \" href=\"UTD.htm?2/55/2930\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef75032 \" href=\"UTD.htm?33/25/34206\">",
"       table 3",
"      </a>",
"      ). Management and risk stratification are discussed further in the text. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 2 to 4 percent of patients with an ACS are mistakenly discharged from the emergency department; these patients have an increase in short-term mortality. Patients whose ACS was missed were more likely to be women less than 55 years of age, non-whites, patients with shortness of breath as the major presenting symptom, and patients with a normal or nondiagnostic initial ECG. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Impact of missed diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94886828\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Goldberger AL. Myocardial Infraction: Electrocardiographic Differential Diagnosis, 4th, Mosby Yeark Book, St. Louis 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/2\">",
"      Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/3\">",
"      Gibler WB, Cannon CP, Blomkalns AL, et al. Practical implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the emergency department. Ann Emerg Med 2005; 46:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/4\">",
"      Pollack CV Jr, Diercks DB, Roe MT, et al. 2004 American College of Cardiology/American Heart Association guidelines for the management of patients with ST-elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med 2005; 45:363.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/6\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/7\">",
"      Pollack CV Jr, Antman EM, Hollander JE, et al. 2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med 2008; 52:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/8\">",
"      Pope JH, Ruthazer R, Beshansky JR, et al. Clinical Features of Emergency Department Patients Presenting with Symptoms Suggestive of Acute Cardiac Ischemia: A Multicenter Study. J Thromb Thrombolysis 1998; 6:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/9\">",
"      Diercks DB, Peacock WF, Hiestand BC, et al. Frequency and consequences of recording an electrocardiogram &gt;10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). Am J Cardiol 2006; 97:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/10\">",
"      Kudenchuk PJ, Maynard C, Cobb LA, et al. Utility of the prehospital electrocardiogram in diagnosing acute coronary syndromes: the Myocardial Infarction Triage and Intervention (MITI) Project. J Am Coll Cardiol 1998; 32:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/11\">",
"      Henrikson CA, Howell EE, Bush DE, et al. Chest pain relief by nitroglycerin does not predict active coronary artery disease. Ann Intern Med 2003; 139:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/12\">",
"      Glickman SW, Shofer FS, Wu MC, et al. Development and validation of a prioritization rule for obtaining an immediate 12-lead electrocardiogram in the emergency department to identify ST-elevation myocardial infarction. Am Heart J 2012; 163:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/13\">",
"      Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012; 126.",
"     </a>",
"    </li>",
"    <li>",
"     Goldberger AL. Clinical Electrocardiography: A Simplified Approach, 6th, Mosby, St. Louis 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/15\">",
"      Fesmire FM, Percy RF, Bardoner JB, et al. Usefulness of automated serial 12-lead ECG monitoring during the initial emergency department evaluation of patients with chest pain. Ann Emerg Med 1998; 31:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/16\">",
"      Parodi O, Uthurralt N, Severi S, et al. Transient reduction of regional myocardial perfusion during angina at rest with ST-segment depression or normalization of negative T waves. Circulation 1981; 63:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/17\">",
"      Turnipseed SD, Trythall WS, Diercks DB, et al. Frequency of acute coronary syndrome in patients with normal electrocardiogram performed during presence or absence of chest pain. Acad Emerg Med 2009; 16:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/18\">",
"      Chase M, Brown AM, Robey JL, et al. Prognostic value of symptoms during a normal or nonspecific electrocardiogram in emergency department patients with potential acute coronary syndrome. Acad Emerg Med 2006; 13:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/19\">",
"      Shlipak MG, Go AS, Frederick PD, et al. Treatment and outcomes of left bundle-branch block patients with myocardial infarction who present without chest pain. National Registry of Myocardial Infarction 2 Investigators. J Am Coll Cardiol 2000; 36:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/20\">",
"      Go AS, Barron HV, Rundle AC, et al. Bundle-branch block and in-hospital mortality in acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. Ann Intern Med 1998; 129:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/21\">",
"      Rathore SS, Gersh BJ, Weinfurt KP, et al. The role of reperfusion therapy in paced patients with acute myocardial infarction. Am Heart J 2001; 142:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/22\">",
"      Panju AA, Hemmelgarn BR, Guyatt GH, Simel DL. The rational clinical examination. Is this patient having a myocardial infarction? JAMA 1998; 280:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/23\">",
"      Swap CJ, Nagurney JT. Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes. JAMA 2005; 294:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/24\">",
"      Goodacre S, Locker T, Morris F, Campbell S. How useful are clinical features in the diagnosis of acute, undifferentiated chest pain? Acad Emerg Med 2002; 9:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/25\">",
"      Castrina FP. Unexplained noncardiac chest pain. Ann Intern Med 1997; 126:663; author reply 663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/26\">",
"      Ros E, Armengol X, Grande L, et al. Chest pain at rest in patients with coronary artery disease. Myocardial ischemia, esophageal dysfunction, or panic disorder? Dig Dis Sci 1997; 42:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/27\">",
"      Grailey K, Glasziou PP. Diagnostic accuracy of nitroglycerine as a 'test of treatment' for cardiac chest pain: a systematic review. Emerg Med J 2012; 29:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/28\">",
"      Edwards M, Chang AM, Matsuura AC, et al. Relationship between pain severity and outcomes in patients presenting with potential acute coronary syndromes. Ann Emerg Med 2011; 58:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/29\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/30\">",
"      Miller CD, Lindsell CJ, Khandelwal S, et al. Is the initial diagnostic impression of \"noncardiac chest pain\" adequate to exclude cardiac disease? Ann Emerg Med 2004; 44:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/31\">",
"      Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/32\">",
"      Mittleman MA, Mintzer D, Maclure M, et al. Triggering of myocardial infarction by cocaine. Circulation 1999; 99:2737.",
"     </a>",
"    </li>",
"    <li>",
"     Braunwald, E, Mark, DB, Jones, RH, et al. Unstable Angina: Diagnosis and Management. Clinical Practice Guideline Number 10 (amended) AHCPR Publication No. 94-0602, Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, US Department of Health and Human Services, Rockville, May 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/34\">",
"      Lee TH, Cook EF, Weisberg M, et al. Acute chest pain in the emergency room. Identification and examination of low-risk patients. Arch Intern Med 1985; 145:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/35\">",
"      Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 2000; 283:3223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/36\">",
"      Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/37\">",
"      Brieger D, Eagle KA, Goodman SG, et al. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest 2004; 126:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/38\">",
"      Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000; 101:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/39\">",
"      Khot UN, Johnson ML, Ramsey C, et al. Emergency department physician activation of the catheterization laboratory and immediate transfer to an immediately available catheterization laboratory reduce door-to-balloon time in ST-elevation myocardial infarction. Circulation 2007; 116:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/40\">",
"      Jernberg T, Lindahl B, Wallentin L. ST-segment monitoring with continuous 12-lead ECG improves early risk stratification in patients with chest pain and ECG nondiagnostic of acute myocardial infarction. J Am Coll Cardiol 1999; 34:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/41\">",
"      Han JH, Lindsell CJ, Storrow AB, et al. The role of cardiac risk factor burden in diagnosing acute coronary syndromes in the emergency department setting. Ann Emerg Med 2007; 49:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/42\">",
"      Lee TH, Rouan GW, Weisberg MC, et al. Clinical characteristics and natural history of patients with acute myocardial infarction sent home from the emergency room. Am J Cardiol 1987; 60:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/43/15034/abstract/43\">",
"      McCarthy BD, Beshansky JR, D'Agostino RB, Selker HP. Missed diagnoses of acute myocardial infarction in the emergency department: results from a multicenter study. Ann Emerg Med 1993; 22:579.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 184 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6001DE224-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15034=[""].join("\n");
var outline_f14_43_15034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40643584\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMMEDIATE ED INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4507342\">",
"      DETERMINING WHO NEEDS AN ELECTROCARDIOGRAM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ECG ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8275033\">",
"      Initial interpretation and criteria for ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Localization of ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Importance of serial ECGs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LBBB or pacemaker",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Historical features increasing likelihood of ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Noncardiac chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ATYPICAL SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CARDIAC BIOMARKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ST elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Non-ST elevation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cardiac arrhythmias during ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Disposition of patient without STEMI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - High-risk patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Low and moderate risk patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      IMPACT OF MISSED DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OBSERVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      REST AND STRESS IMAGING TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40643584\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94886828\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/184\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/184|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?2/55/2930\" title=\"algorithm 1\">",
"      Schema manage suspected AMI ER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/63/44022\" title=\"algorithm 2\">",
"      Adult cardiac arrest algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/21/20819\" title=\"algorithm 3\">",
"      Adult tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/16/1280\" title=\"algorithm 4\">",
"      Adult bradycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/184|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/12/11467\" title=\"table 1\">",
"      Chest pain in ER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/43/12989\" title=\"table 2A\">",
"      Other diagnoses chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/29/43483\" title=\"table 2B\">",
"      Characteristics of major noncardiac causes of chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/25/34206\" title=\"table 3\">",
"      Rapid overview ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/16/23820\" title=\"table 4\">",
"      Contraindications to fibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/29/2524\" title=\"table 5\">",
"      Probability of MI in chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/17/5406\" title=\"table 6\">",
"      Chest pain differentiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/59/4027\" title=\"table 7\">",
"      Killip classification of acute MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/184|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/21/43354\" title=\"waveform 1\">",
"      ECG acute inferior and right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/18/43306\" title=\"waveform 2A\">",
"      ECG in evolving anterior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/35/43578\" title=\"waveform 2B\">",
"      ECG late evolution of anterior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?39/58/40874\" title=\"waveform 3\">",
"      Acute anteroseptal MI tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/53/42842\" title=\"waveform 4\">",
"      Acute lateral MI tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41113?source=related_link\">",
"      Clinical features and diagnosis of coronary heart disease in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=related_link\">",
"      Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=related_link\">",
"      Conduction abnormalities after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9431?source=related_link\">",
"      Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2537?source=related_link\">",
"      Elevated cardiac troponin concentration in the absence of an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20090?source=related_link\">",
"      Evaluation of chest pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31961?source=related_link\">",
"      Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=related_link\">",
"      Evaluation of the adult with dyspnea in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24566?source=related_link\">",
"      Nitrates in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29578?source=related_link\">",
"      Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=related_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=related_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=related_link\">",
"      Supraventricular arrhythmias after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_43_15035="Treatment of PMS";
var content_f14_43_15035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Therapies for the premenstrual syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatments with demonstrated efficacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serotonin reuptake inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alprazolam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Agents that suppress ovulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        GnRH agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Danazol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatments with possible efficacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ineffective treatments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progesterone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin supplements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietary restrictions",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15035=[""].join("\n");
var outline_f14_43_15035=null;
var title_f14_43_15036="Postbronchodilator FEV1";
var content_f14_43_15036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75664%7EPULM%2F52958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75664%7EPULM%2F52958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Postbronchodilator FEV1 as a marker for disability in asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        FEV1, percent predicted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &gt; lower limit of normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        70 to lower limit of normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        60 to 69",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        50 to 59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Thoracic Society. Guidelines for the evaluation of impairment/disability in patients with asthma. Am Rev Respir Dis 1993; 147:1056.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessing impairment in patients with asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reversibility of FEV1 (percent FEV1",
"change)",
"       </td>",
"       <td class=\"subtitle1\">",
"        or",
"       </td>",
"       <td class=\"subtitle1\">",
"        Airway Hyperresponsiveness",
"(PC20 mg/mL or equivalent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &lt;10",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        &nbsp;",
"        <br/>",
"       </td>",
"       <td>",
"        &gt;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        10-19",
"       </td>",
"       <td>",
"        8-&gt;0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        20-29",
"       </td>",
"       <td>",
"        0.5-&gt;0.125",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        &ge;30",
"       </td>",
"       <td>",
"        &le;0.125",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from American Thoracic Society. Guidelines for the evaluation of impairment/disability in patients with asthma. Am Rev Respir Dis 1993; 147:1056.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15036=[""].join("\n");
var outline_f14_43_15036=null;
var title_f14_43_15037="Vision screen infants children";
var content_f14_43_15037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Eye examination for infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        History",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examination",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Newborn to 6 months",
"       </td>",
"       <td>",
"        <p>",
"         Birth weight &lt;1500 gm",
"        </p>",
"        <p>",
"         Family history of:",
"        </p>",
"        <p>",
"         Congenital cataracts",
"        </p>",
"        <p>",
"         Retinoblastoma",
"        </p>",
"        <p>",
"         Metabolic or genetic disease",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Vision assessment (fix and follow)",
"        </p>",
"        <p>",
"         External eye examination (lids, orbit, cornea, iris)",
"        </p>",
"        <p>",
"         Ocular motility",
"        </p>",
"        <p>",
"         Pupillary response",
"        </p>",
"        <p>",
"         Simultaneous red reflex",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Refer to ophthalmologist:",
"        </p>",
"        <p>",
"         Positive history or abnormal examination (eg, abnormal red reflex, pupillary asymmetry of &gt;1 mm, unilateral ptosis)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        6 months to 3 yrs",
"       </td>",
"       <td>",
"        <p>",
"         Developmental delay",
"        </p>",
"        <p>",
"         Neurologic difficulty",
"        </p>",
"        <p>",
"         Systemic disease associated with eye abnormalities",
"        </p>",
"        <p>",
"         Does the infant recognize faces and objects?",
"        </p>",
"        <p>",
"         Does the infant fix and follow?",
"        </p>",
"        <p>",
"         Do the parents notice:",
"        </p>",
"        <p>",
"         Eye deviation?",
"        </p>",
"        <p>",
"         Tearing?",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Above tests plus:",
"        </p>",
"        <p>",
"         Corneal light reflex",
"        </p>",
"        <p>",
"         Cover-uncover test",
"        </p>",
"        <p>",
"         Age-appropriate visual acuity (eg, fix and follow)",
"        </p>",
"        <p>",
"         Ophthalmoscopy if possible",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Refer to ophthalmologist:",
"        </p>",
"        <p>",
"         Above plus:",
"        </p>",
"        <p>",
"         Eye preference",
"        </p>",
"        <p>",
"         Ocular alignment abnormalities",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        3 to 5 yrs",
"       </td>",
"       <td>",
"        <p>",
"         Above plus:",
"        </p>",
"        <p>",
"         Do the parents notice:",
"        </p>",
"        <p>",
"         Abnormal head posturing?",
"        </p>",
"        <p>",
"         Squinting or blepharospasm?",
"        </p>",
"        <p>",
"         Eye deviation?",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Above tests plus:",
"        </p>",
"        <p>",
"         Monocular visual acuity*:",
"        </p>",
"        <p>",
"         Snellen letters or numbers",
"        </p>",
"        <p>",
"         Tumbling E",
"        </p>",
"        <p>",
"         HOTV",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Picture tests",
"        </p>",
"        <p>",
"         Stereopsis",
"         <sup>",
"          &Delta;",
"         </sup>",
"         (Random dot E)",
"        </p>",
"        <p>",
"         Ophthalmoscopy if possible",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Confirm abnormal visual acuity with repeat testing",
"        </p>",
"        <p>",
"         Refer to ophthalmologist:",
"        </p>",
"        <p>",
"         Above plus:",
"        </p>",
"        <p>",
"         Visual acuity worse than 20/40 in one or both eyes",
"        </p>",
"        <p>",
"         Visual acuity difference greater than two lines between eyes",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &gt;6 yrs",
"       </td>",
"       <td>",
"        Above tests",
"       </td>",
"       <td>",
"        <p>",
"         Above tests plus:",
"        </p>",
"        <p>",
"         Monocular visual acuity*",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Confirm abnormal visual acuity with repeat testing",
"        </p>",
"        <p>",
"         Refer to ophthalmologist:",
"        </p>",
"        <p>",
"         Above plus:",
"        </p>",
"        <p>",
"         Visual acuity worse than 20/30 in one or both eyes",
"        </p>",
"        <p>",
"         Visual acuity difference greater than two lines between eyes",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Testing distance of 10 feet is recommended; testing with line of figures rather than single figures is preferred.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     HOTV is an optotype vision chart using only the letters H, O, T, and V.",
"     <br/>",
"     &Delta; Stereopsis is the ability to perceive depth in three dimensions.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Essman SW, Essman TF. Am Fam Phys 1992; 46:1243; Hartmann EE, Dobson V, Hainline L, et al. Pediatrics 2000; 106:1105 and Eye examination in infants, children, and young adults by pediatricians. Pediatrics 2003; 111:902.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15037=[""].join("\n");
var outline_f14_43_15037=null;
var title_f14_43_15038="Staging ovarian peritoneal carcinoma";
var content_f14_43_15038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Staging ovarian and peritoneal carcinoma (TNM and International Federation of Gynecology and Obstetrics [FIGO])",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Primary tumor (T)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        TNM categories",
"       </td>",
"       <td class=\"subtitle2\">",
"        FIGO stages",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        No evidence of primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T1",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        I",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"2\">",
"        Tumor limited to ovaries (one or both)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1a",
"       </td>",
"       <td class=\"sublist_other\">",
"        IA",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Tumor limited to one ovary; capsule intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1b",
"       </td>",
"       <td class=\"sublist_other\">",
"        IB",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1c",
"       </td>",
"       <td class=\"sublist_other\">",
"        IC",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T2",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        II",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"2\">",
"        Tumor involves one or both ovaries with pelvic extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T2a",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIA",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Extension and/or implants on uterus and/or tube(s). No malignant cells in ascites or peritoneal washings.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T2b",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIB",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Extension to and/or implants on other pelvic tissues. No malignant cells in ascites or peritoneal washings.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T2c",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIC",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T3",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        III",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"2\">",
"        Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T3a",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIIA",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T3b",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIIB",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T3c",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIIC",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Regional lymph nodes (N)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        TNM categories",
"       </td>",
"       <td class=\"subtitle2\">",
"        FIGO stages",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        Regional lymph nodes cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        No regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        IIIC",
"       </td>",
"       <td colspan=\"2\">",
"        Regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Distant metastasis (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        TNM categories",
"       </td>",
"       <td class=\"subtitle2\">",
"        FIGO stages",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        No distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M1",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td colspan=\"2\">",
"        Distant metastasis (excludes peritoneal metastasis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         pTNM pathologic classification.",
"        </strong>",
"        The pT, pN, and pM categories correspond to the T, N, and M categories.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Anatomic stage/prognostic groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage I",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IA",
"       </td>",
"       <td>",
"        T1a",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IB",
"       </td>",
"       <td>",
"        T1b",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IC",
"       </td>",
"       <td>",
"        T1c",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage II",
"       </td>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIA",
"       </td>",
"       <td>",
"        T2a",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIB",
"       </td>",
"       <td>",
"        T2b",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIC",
"       </td>",
"       <td>",
"        T2c",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage III",
"       </td>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIIA",
"       </td>",
"       <td>",
"        T3a",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIIB",
"       </td>",
"       <td>",
"        T3b",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Stage IIIC",
"       </td>",
"       <td>",
"        T3c",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IV",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Liver capsule metastasis T3/Stage III; liver parenchymal metastasis M1/Stage IV. Pleural effusion must have positive cytology for M1/Stage IV.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15038=[""].join("\n");
var outline_f14_43_15038=null;
var title_f14_43_15039="Divertic obstruct Hypaque enema";
var content_f14_43_15039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diverticular obstruction on hypaque enema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hypaque enema in a 74-year-old woman with bloating and ribbon-like stools for several years reveals a persistent area of narrowing (arrow) in the mid-sigmoid colon measuring 2 cm in length. It is not possible to distinguish between a diverticular stricture and carcinoma radiographically; resection of the affected segment is mandatory.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_43_15039=[""].join("\n");
var outline_f14_43_15039=null;
